Available online at **www.ijmrhs.com**

ISSN No: 2319-5886

International Journal of Medical Research & Health Sciences, 2021, 10(12): 36-63

Impact of Uric Acid in Malaria Outcomes

Mosab Nouraldein Mohammed Hamad[1*], Sufian Khalid M. Noor[2], Awadalla H Kashif[3], Mohammed Medani Eltayeb[4], Bader Saud Alotaibi[5], Elizabeth Popova[6], Rania Saad Abdulgader[7], Abdelgadir Elamin Eltom[8], Shafie Abdulkadir Hassan[9], Yassin Bakri Salih[10], Tarig Mohamed Elfaki1[1] and Mohammed Ahmed Ibrahim Ahmed[1]

[1]Microbiology Department, Faculty of Medicine, Nile Valley University, Atbara, Sudan

[2]Medicine Department, Faculty of Medicine, Nile Valley University, Atbara, Sudan

[3]Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan

[4]Faculty of Medical Laboratory Sciences, Alneelain University, Khartoum, Sudan

[5]Department of Laboratory Science, College of Applied Medical Sciences, Alquwayiyah, Shaqra University, Saudi Arabia Kingdom

[6]College of Health and Allied Sciences, St. Joseph University in Tanzania, Dar Es Salaam, United Republic Of Tanzania

[7]Department of Clinical Laboratory Sciences, Prince Sultan Military College of Health Sciences, Dammam, Saudi Arabia Kingdom

[8]Medical Laboratories Department, College of Health Sciences, Gulf Medical University, Ajman, United Arab Emirates

[9]Department of Medical Laboratory Sciences, Jamhuriya University of Science and Technology, Mogadishu, Somalia

[10]Reference Diagnostic Laboratory, Ministry of Health and Population, Atbara, River Nile State, Sudan

[11]Medical Laboratory Sciences, Academy of Health Science, Federal Ministry of Health, Khartoum, Sudan-a

[*]Corresponding e-mail: musab.noor13@gmail.com

ABSTRACT

Up to the date variations of malaria pathogenesis between human populations signify important trouble facing scholars concerned with malaria pathology. Pathogen-associated molecular patterns may be one of the main keys to the well understanding of malaria mechanism and dissimilarity of clinical outcomes of the disease between people. Uric acid is regarded as a dangerous alarming metabolite, resulting from plasmodium activity inside infected red blood cells, furthermore, levels of uric acid correlate with the development of intracellular malaria parasites. Hypoxanthine resulting from the breakdown of haemoglobin by Plasmodium species is very important in malaria pathogenesis, because plasmodia use it as a nutrient and after rupture of schizonts the remaining of it is converted to uric acid due to the action of Xanthine oxidase, and that gave a strong linkage between malaria pigment density and severity of malaria infection. Uric acid is the main cause of arthritis which is one of the common clinical features of malaria, it induces the inflammatory response and many cytokines involved, genes related to hyperuricemia involved discrepancy of clinical outcomes between malaria patients.

Keywords: Malaria parasites, Uric acid, Hypoxanthine, Uric acid-related genes

Abbreviations: NLRP3: NLR Family Pyrin domain containing 3, IL-1: Interleukin-1, DNAse: Deoxyribonuclease, DNA: Deoxyribonucleic Acid, TNF: Tumor Necrosis Factor, IL-1β: Interleukin 1 beta, IL-6: Interleukin-6, FLT3: Fms-Like Tyrosine kinase 3, CD8: Cluster of Differentiation 8, CD8α: Cluster of Differentiation 8 alpha, TNFα: Tumor necrosis factor-alpha, ICAM-1: Intercellular Adhesion Molecule-1, DCs: Dendritic Cells, XO: Xanthine Oxidase, PBMCs: Peripheral Blood Mononuclear Cell, IL-10: Interleukin-10,

MSU: Monosodium Urate, GLUT9: Glucose Transporter 9, NPT1:Nicotinate/Phosphoribosyltransferase-1, SLC17A1: Solute Carrier Family 17 Member 1, URAT1: Urate anion exchanger 1, OAT4: Organic Anion Transporter 4, NPT4: Sodium phosphate transporter 4, NPT5: Sodium/phosphate co-transporter homolog, MCT9: Monocarboxylate Transporter 9, ABCG2: ATP-Binding Cassette subfamily G member 2, ABCC4: ATP-Binding Cassette subfamily C member 4, KCNQ1: Potassium Voltage-Gated Channel Subfamily Q Member 1, PDZK1: PDZ domain containing 1, NIPAL1: Nipa-Like Domain containing 1, IL-8: Interleukin-8, IL-12B: Interleukin-12 Beta, IL-23R: Interleukin-23 Receptor, MCP-1: Monocyte Chemoattractant Protein 1,

CCL2: CC Chemokine Ligand 2, PPARGC1B: Peroxisome Proliferator-Activated Receptor-γ Coactivator 1β,

TLR4: Toll-Like Receptor 4, CD14: Cluster of Differentiation 14, CARD8: Caspase Activation and Recruitment Domain 8, P2X7R: Purinergic receptor P2X ligand-gated ion channel 7, EGF: Epidermal Growth Factor, A1CF: Apobec-1 Complementation Factor, HNF4G: Hepatocyte Nuclear Factor 4 Gamma, TRIM46: Tripartite Motif 46, LRP2: Low-density Lipoprotein Receptor-Related Protein 2, GKRP: Glucokinase Regulatory Protein, ADRB3: Beta-3-Adrenergic Receptor, ADH1B: Alcohol Dehydrogenase 1B, ALDH2: Aldehyde Dehydrogenase 2, COMT: Catechol-O-Methyltransferase, MAOA: Monoamine Oxidases A, PRKG2: Protein Kinase, cGMP-dependent 2, WDR1: WD-Repeat protein 1, ALPK1: Alpha-Kinase 1, CARMIL: Capping protein ARP2/3 and Myosin-I Linker, RFX3: Regulatory Factor X 3, BCAS3: Breast Cancer Amplified Sequence 3, CNIH-2: Cornichon-2, MYL2: Myosin Light chain-2, CUX2: Cut-like homeobox 2, APCs: Antigen Presenting Cells, AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, ATP: Adenosine Triphosphate, DAMPs: Damage-Associated Molecular Patterns, IgE: Immunoglobulin E, IFNγ: Interferon gamma, DLPFC: Dorsolateral Prefrontal Cortex, RANTES: Regulated on Activation, Normal T Expressed and Secreted, SNP: Single Nucleotide Polymorphism, GWAS: Genome-Wide Association Study, MEFV: Mediterranean Fever, DHEA: Dehydroepiandrosterone

INTRODUCTION

Malaria is a protozoan parasitic disease caused by one or more of the six known species of plasmodium which infect humans (*Plasmodium vivax*, *Plasmodium ovale wallickeri*, *Plasmodium ovale curtisi*, *Plasmodium malariae*, and *Plasmodium knowlesi*) [1].

It stays an upsetting international health crisis. Globally, an estimated 300-500 million people are infected with malaria every year, ensuing in 1.5-2.7 million deaths yearly. Owing to the raise in the global move to and migration of people from regions endemic for malaria, the frequency of imported cases of malaria in industrial countries has increased. About 10,000-30,000 travellers from developed countries are probable to contract malaria annually. As well, drug-resistant *Plasmodium falciparum* malaria persists to extend and presently involves almost all regions of the world. A rising number of travellers are exposed to drug-resistant plasmodia [2].

Malaria offers a broad array of systemic clinical outcomes and several life intimidating organ pathologies, counting the lethal cerebral malaria. Similar to various other communicable diseases, it is an inflammatory reaction-induced disease, and positive results to infection rely on delicately tuned regulation of immune responses that competently remove plasmodia and let defensive immunity build up [3].

REVIEW OF LITERATURE

The common sight of the pathogenesis of communicable disease has experienced model transform in the past few years, chiefly in the last five years or so in which the phrase “cytokine storm” has to turn out well-liked currency [4].

Uric acid is the last oxidation artifact of purine metabolism and is free in huge quantities by deceased cells. In physiological situations, it presents as a mono-ionic urate and shapes insoluble mono-urate crystals. It is a significant antioxidant in plasma and can induce protective anti-inflammatory responses in vascular and other diseases. Though,

the extreme configuration of uric acid encourages harmful conditions, such as severe and chronic inflammatory arthritis, gout, and particular metabolic syndromes. The pathogenic function of uric acid is owing to the stimulation of NLRP3 inflammasome, which consequences in caspase 1 stimulation and alteration of pro-IL-1 into active IL-1 and throughout malaria, a huge number of parasite-engulfed macrophages, neutrophils, and other immune cells pass away, which probable discharge high concentrations of uric acid. Notably, a considerable quantity of uric acid is shaped throughout purine nucleotide metabolism by plasmodia and gathers as an impulse in infected red blood cells.

Huge quantities of hypoxanthine also mount up in plasmodia infected red blood cells. The uric acid impulsive and hypoxanthine discharged to the blood upon schizont rupture. In the blood flow, hypoxanthine is oxidized to uric acid. In harmony with its pathogenic task, higher concentrations of uric acid are set up in the blood circulation of patients having rigorous malaria [3].

Besides hypoxanthine, *P. falciparum*-infected red blood cells were found to build up uric acid impulsive in the cytosol of the intra-erythrocytic plasmodium, which discharged to the extracellular surroundings jointly with daughter plasmodia upon erythrocyte burst. Uric acid impulsive also set up in infected red blood cells newly isolated from patients with *P. vivax* and *P. falciparum* infections, signifying that uric acid precipitates are a preserved characteristic of *Plasmodium spp*.

It is significant to mention that there is no raise in the measure of uric acid exist in infected red blood cells, suggestive that the action of red blood cell uric acid transporters is not influenced by infection; but higher levels of hypoxanthine build up in infected red blood cells. This is dependable with the lack of xanthine dehydrogenase activity in *Plasmodium* and red blood cells and would involve that infection with *Plasmodium* makes precipitation of pre-existing uric acid within the red blood cell, but not the breakdown of hypoxanthine into uric acid.

During a burst of infected red blood cells, the discharge of uric acid impulsive in the bloodstream is probable to stimulate a potent inflammatory reaction. Part of lysates of *P. falciparum*-infected red blood cells demonstrated that the activator effect on human dendritic cells was intense in the bit part and was incompletely responsive to uricase and DNAse, proving a vital responsibility for both plasmodium DNA and uric acid in the inflammatory reaction to the malaria parasite.

P. falciparum-derivative uric acid furthermore participates in the emission of immune modulators, such as TNF, IL-1β, and IL-6, by peripheral blood mononuclear cells *in vitro*. These immune modulators rose in malaria patients and were accompanied by the severity of the disease, signifying once more an inflammatory function for uric acid in malaria. Another task for uric acid in *Plasmodium* immune response was later suggested, as impulsive uric acid provokes the discharge of Flt3 ligand from mast cells, which in turn, provokes expansion of CD8α dendritic cells that force stimulation of CD8 T-cells. *Plasmodium* built up hypoxanthine and uric acid precipitates are probable to take key functions in the man immune response to the plasmodium, not just as inflammatory initiators, but also as controllers of specific immune responses to the plasmodium.

A significant aspect to think about in every uric acid-induced inflammatory reaction absence of uricase action in humans and other upper primates. It is usually accepted that the loss of uricase was adaptive adjusted, as kidneys pick up most of the filtered uric acid.

Due to the absence of uricase activity, there is a reasonable raise in serum uric acid concentration, attainment 2 mg/dL-4 mg/dL, which was detected in primitive man cultures and apes with the absence of uricase action and has risen to about 6 mg/dL in western cultures because of red meat enriched food. This concentration is extremely near to saturation and precipitation threshold in plasma >7 mg/dL and would produce suitable environments for precipitation of uric acid upon slight raises. This suggested for dying cells freeing uric acid, which would work as an alarming or ‘danger signal’, and may probably happen throughout a *Plasmodium* infection, where the discharge of soluble hypoxanthine and uric acid, and succeeding configuration of uric acid precipitates would outcome in raised uric acid levels in plasma.

Higher concentrations of plasma uric acid correlate with parasitemia and disease development in *P. falciparum* infections. In African kids, plasma uric acid concentrations increased from 3.3 mg/dL to 4.60 mg/dL in mild malaria, reaching concentrations higher than 5.5 mg/dL in complicated malaria.

It is not obvious whether the raise in uric acid in the bloodstream is owing to damaged kidney function, a recurrent result in malaria, and/or to discharge of parasite built up hypoxanthine and uric acid precipitates.

A straight function for uric acid in malaria-induced inflammation proposed by an experimental study in which administration of allopurinol, an inhibitor of xanthine dehydrogenase and so the formation of uric acid, decreased inflammatory reactions in malaria patients. This clinical study achieved to check the anti-Plasmodial action of allopurinol, which is a purine analogue with action against trypanosomatid parasites. Despite the noticed absence of anti-plasmodial action, *P. falciparum*-infected patients cured with allopurinol besides the anti-malarial drug quinine had considerably quicker reductions in fever and splenomegaly contrasted to patients cured with just quinine.

The interface between *P. falciparum*-infected red blood cells and host endothelial cells is influenced by inflammation, as cytokines such as TNF-α cause raised expression of endothelial cell cytoadhesive surface proteins, such as ICAM-1, influencing the outcome of cerebral malaria. In Man, hyperuricemia seems like an important independent risk factor for endothelial damage.

A task for uric acid in endothelial dysfunctions accompanied with *P. falciparum* infection was also lately proposed. In Malian kids with a malaria episode, raised plasma uric acid concentrations to correlate not merely with plasmodium density and disease severity, but also with signs of endothelial pathologies (soluble ICAM-1 and thrombomodulin). Detaching of thrombomodulin that is usually bound to thrombin at the cell surface directs to a surplus of active thrombin, which in turn causes platelet activation and aggregation. As platelet activation raises the connection of infected red blood cells to endothelial cells, potentiating the cytotoxicity to the endothelium, uric acid could probably take part in endothelial dysfunctions through this mechanism.

In malaria, stimulation of natural immunity is a key aspect in the equilibrium between plasmodium endurance and host defence. The use of uric acid as a danger signal a result of co-evolution to use this caution system to activate a high inflammatory reaction that could be critical to *Plasmodium* survival, chiefly in human beings and primates that uricase activity deficient [5].

High levels of soluble uric acid stimulate the discharge of inflammatory intermediaries from dissimilar cell types, signifying that the soluble uric acid shaped through hypoxanthine breakdown could also take part in malaria resulting in inflammatory reaction.

Infected erythrocytes accumulate in definite organs, like the spleen, where they are also detected in the extra-vascular tissue. Likely, this condition could also ease crystallization, as high local levels of uric acid over the threshold of crystallization might simply be attained upon schizont burst and hypoxanthine discharge in these organs, particularly in harmonized infections. Uric acid may also be shaped in the brain when infected red blood cells are sequestered in capillaries, thus shaping a micro-setting that would help crystallization.

Plasmodium derivative hypoxanthine should also be transformed to uric acid in the phagosome of DCs and macrophages upon uptake and breakdown of infected red blood cells, as they express XO. Inside this restricted environment, high levels of uric acid would simply be attained [6].

Studies were done by Orengo JM, et al. prove that uric acid takes part considerably in the emission of TNF, IL-1β, and IL-6 by PBMCs in response to *P. falciparum*-infected red blood cells. These three immune modulators are believed indicative of inflammatory responses, high in malaria patients, and accompanied by the severity of malaria. TNF has usually been used as a reporter to recognize the 'malarial toxin', a name given to the pro-inflammatory molecules resulting from *Plasmodium*. Emission of TNF by PBMC in response to *P. falciparum* correlates with the stage of the plasmodium, with schizonts inducing the greatest TNF responses and early ring stages not causing any response. Fascinatingly, we prove that the gathering of hypoxanthine also appears to rise with a sequence of the parasite developmental cycle. Also, set up raises in IL-10, a well-known regulatory cytokine, that is reliant on the configuration of uric acid. The discharge of IL-10 after 9 h of incubation is possibly a result of the early inflammatory wave of inflammatory cytokines obvious before at 3 h, as inflammatory cytokines such as TNF cause IL-10 discharge from immune cells. So, the lessening in IL-10 discharge after the suppression of the uric acid pathway could be a result of the reduced early inflammatory cytokines [7].

A study done by Gomes LT, et al. showed that lower serum levels of uric acid detected during the acute phase of *P. vivax* malaria contrasted to those in its restorative phase [8].

The uric acid collection seems to spread out to compete with the body load of oxidants as an adjustment reaction. The high urate concentration in malaria patients could point to an adaptive method against the toxins discharged by the immune cells against the plasmodia. This is in line with former documents, of increased serum uric acid levels as an outcome of a physiologic reaction to oxidative stress, giving a counter control raise in antioxidant defences. Consistent with Lopera-Mesa, et al., uric acid is a consistent and reliable biomarker of an important generation of oxidants in malaria. Uric also works as a mend mediator of oxidative damage to DNA bases, 24 this an extra cause why uric acid was high in malaria patients after the cure [9]. Gout is a widespread type of inflammatory arthritis resulting from hyperuricemia and accumulation of Monosodium Urate (MSU) crystals. It is also measured as complex chaos in which several genetic aspects are recognized to go with its vulnerability and/or clinical results. main genes that linked with gout form GLUT9, NPT1 (SLC17A1), URAT1, OAT4, NPT4 (SLC17A3), NPT5 (SLC17A4), MCT9, ABCG2, ABCC4, KCNQ1, PDZK1, NIPAL1, IL1β, IL-8, IL-12B, IL-23R, TNFA, MCP-1/CCL2, NLRP3, PPARGC1B, TLR4, CD14, CARD8, P2X7R, EGF, A1CF, HNF4G, and TRIM46, LRP2, GKRP, ADRB3, ADH1B, ALDH2, COMT, MAOA, PRKG2, WDR1, ALPK1, CARMIL (LRRC16A), RFX3, BCAS3, CNIH-2, MYL2- CUX2 and FAM35A. The proteins prearranged by these genes chiefly task in urate transfer, inflammation, natural immunity, and metabolism [10].

A study done by Bertrand KE recognized that; plasma uric acid raised considerably in malaria patients contrasted to healthy controls. Raise the rate of purine catabolism and assembly of urate is a common occurrence in malaria infection due to hemolysis and oxidation of nucleic acids by reactive oxygen species formed. The non-considerable boost of plasma uric acid with parasite density is probably attributed to the low parasitemia [11].

Uric acid concentrations boost through episodes of uncomplicated malaria and more augment detected in complicated malaria. Concentrations of serum uric acid also correlate with malaria parasitemia. It is rising as an essential inflammatory fragment in malaria. Not merely is uric acid recognized in the precipitated shape in infected red blood cells, but higher levels of hypoxanthine, a precursor for uric acid, also build up in infected red blood cells [12]. Also, scholars noticed that; hypoxanthine is a necessary part of the development of erythrocytic *Plasmodium falciparum* in a serum-free medium [13].

TLR9 is a pattern recognition receptor principally detected on intracellular endosomes in Antigen Presenting Cells (APCs). Its function in malaria has been contentious, but current accounts show that plasmodium DNA-hemozoin complexes activate TLR9-dependent assembly of a family of cytokines called type I Interferons (IFNs) by APCs. These immune modulators are concerned with regulating viral infections but can also repress immune responses through malaria.

Guermonprez, et al. found that TLR9-dependent type I IFN making by an APC population activates the synthesis of xanthine dehydrogenase in the lung, chiefly by endothelial cells throughout *P. chabaudi* and *P. berghei* ANKA infections. As an outcome, there was an augment in uric acid configuration from xanthine or hypoxanthine discharged by the burst of parasitized red blood cells, which then activated mast cells to liberate Flt3l from their cell surface to encourage CD8α+ DC extension, resultant in amplified antigen-specific CD8+ T-cell activation.

Despite the absence of potent molecular and cellular proof for host immune participation in the pathogenesis of rigorous malaria, genetic involvement studies and correlations between malaria severity and systemic inflammatory cytokine concentrations hold up this notion. Guermonprez, et al. also tested Kenyan kids with uncomplicated and complicated malaria and detected a positive correlation between plasma Flt3l quantities and malaria severity, with a similar connection between plasma Flt3l levels and occurrences of circulating BDCA3+ DCs, but not of other DC subsets. Alike to what was noticed in the experimental malaria models, infected kids with the uppermost plasma Flt3l quantities also had high frequencies of stimulated CD8+ T cells, but not CD4+ T cells, in the blood. Thus, Kenyan kids with complicated malaria appeared to prove some of the key aspects of the Flt3l-dependent CD8α+ DC stimulation axis of CD8+ T cells recognized in the experimental malaria research with *P. berghei* ANKA, in which CD8+ T cells were pathogenic [14].

High uric acid concentrations may take part in the pathogenesis of *P. falciparum* malaria by stimulating immune cells to release inflammatory cytokines [15]. Malaria pigment is a by-product of parasite haemoglobin breakdown studied in malaria for several years. Though malaria pigment is considered a benign by-product of plasmodium metabolism, its pathogenic function suggested by clinical records viewing that the intraleukocytic malaria pigment

content correlates more intimately with mortality than peripheral parasite density, and by the inspection that tissue malaria pigment correlates both with malarial anaemia and with endurance from cerebral malaria. Following *in vitro* studies recognized an inflammatory response to malaria pigment, signifying that this plasmodium product may take part in the extreme inflammation of complicated malaria. The molecular method by which malaria pigment stimulates the inflammatory response was unidentified, until Coban, et al. recognized that malaria pigment's pro-inflammatory activities needed TLR9 and the TLR adaptor molecule MyD88. Malaria pigment leads to the discharge of uric acid and the inflammasome-dependent production of IL-1. Certainly, inoculation of sHz into the peritoneal cavity of mice resulted in a 3-fold augment in uric acid level, and mice pre-treated with allopurinol or allopurinol and uricase proved much drop recruitment of neutrophils in response to sHz [16].

High uric acid concentrations may take part in malaria pathogenesis by destructive influence on endothelium and causing a pro-coagulant state. The correlation between uric concentrations and parasitemia proposes that parasitized red blood cells are one probable source of surplus uric. Uric acid-induced flaking of endothelial TM may signify new machinery of malaria pathogenesis, in which activated thrombin causes fibrin deposition and platelet aggregation in microvessels, also increased level of uric acid found in *P. vivax* malaria patients [17,18].

Extracellular Reactive Oxygen Species (ROS) formed by Xanthine Oxidase (XO), an enzyme up-regulated throughout malaria, make potent inflammatory cytokine response in prime human monocyte-derived macrophages. In malaria patients, high plasma XO activity correlates with high concentrations of inflammatory cytokines and with the progress of cerebral malaria. Incubation of macrophages with plasma from these patients can cause an XO-dependent inflammatory cytokine response, recognizing a host reason as an elicit inflammation in malaria. XO-produced ROS also boosts the production of pro-IL-1β [19].

Maori and Pacific citizens' raised rates of the arthritic joint disease gout linked to evolutionary alterations protecting against malaria, University of Otago researchers consider. The twelve percent rate in Maori men-gout influences men more than women-is three times upper than that of Pakeha men. Fourteen percent of Pacific men were influenced. Gout induces severe pain, often in the big toe, and results from the high concentration of uric acid, which can shape crystals that lodge in joints. The disease is connected to high consumptions of sweet drinks and alcohol. But Otago University biochemist, Tony Merriman, attributes gout sixty percent to genetic aspects and only forty percent to lifestyle and surroundings, counting food. He and his co-workers are examining the thought that Maori and Pacific inhabitants' more uric acid concentrations may outcome from an evolutionary alteration in their ancestors' genes tens of centuries ago protecting against the mosquito-borne infection malaria. Malaria has most likely never presented in Polynesia, say, Dr. Merriman, biological anthropologist Professor Lisa Matisso-Smith and doctoral student Anna Gosling in a medical journal paper. "However the ancestral inhabitants passed through and may have originated in regions with endemic malaria, called New Guinea, the Solomon Islands, and Vanuatu" [20].

ATP-Binding Cassette transporter G2 (ABCG2), also identified as Breast Cancer Resistance Protein (BCRP), is recognized as a high-capacity urate exporter and its dysfunction has gone with Serum Uric Acid (SUA) concentrations and gout/hyperuricemia risk. But, pathophysiologically key pathway(s) accountable for the ABCG2-mediated urate emission unidentified [21]. Genetic difference in ABCG2 (rs2231142, Q141K), encoding a uric acid transporter, accompanied with gout in varied people [22].

A study done by Wrigley R, et.al, showed that; In Europeans and Polynesians, the ABCG2 141K (T) allele linked with gout applying hyperuricaemic controls [23]. Dissimilar SLC2A9, which is a potent risk factor for gout in both Maori and Pacific Island people, ABCG2 rs2231142 has a powerful effect merely in people of Western Polynesian ancestry [22]. SLC2A9 splice variants act as high-capacity urate transporters and are one of the first practical characterizations of findings from genome-wide association scans [24].

Renal hypouricemia is inborn chaos characterized by damaged renal urate (uric acid) reabsorption and following low serum urate concentrations, with severe obstacles such as exercise-induced acute renal failure and nephrolithiasis. Formerly recognized SLC22A12, also recognized as URAT1, as a causal gene of renal hypouricemia. Although, hypouricemic patients with no URAT1 mutations, as well as genome-wide association studies between urate and SLC2A9 (also called GLUT9), involve that GLUT9 could be an extra contributory gene of renal hypouricemia [25].

Merely human beings and higher primates have high uric acid blood levels. While high uric acid induces gout, it is connected with man longevity owing to its hypothetical antioxidant role. Current studies show that p53 is an important

task in cellular metabolism. For instance of this is an antioxidant role that potentially takes part in tumour repression. Researchers recognized the uric acid transporter SLC2A9 (also known as GLUT9) as a direct p53 target gene and a key downstream effector in the lessening of Reactive Oxygen Species (ROS) through transporting uric acid as a resource of antioxidant. Oxidative stress caused SLC2A9 expression in a p53-dependent way, and suppression of SLC2A9 by small interfering RNA (siRNA) or anti-gout drugs such as probenecid considerably raised ROS concentrations in a uric acid-dependent way and greatly sensitized cancer cells to chemotherapeutic drugs. Evenly, expression of SLC2A9 lessened ROS and prevent DNA break and cell fatality, suggestive of its antioxidant role. The augmented creation of ROS because of p53 loss saved by SLC2A9 expression. A p53-SLC2A9 pathway is a new antioxidant method that employs uric acid to keep ROS homeostasis and stop the build-up of ROS-associated damage [26]. By the Pentose Phosphate Pathway (PPP), p53 restrains glucose use, NADPH making, and biosynthesis. The p53 protein links to Glucose-6-Phosphate Dehydrogenase (G6PD), the primary and speed-restrictive enzyme of the PPP, and stops the configuration of the dynamic dimer. A p53 mutants lack the G6PD-inhibitory activity. So, promoted PPP glucose flux owing to p53 suppression may boost glucose use [27].

Particular polymorphisms in the genes regulating renal urate transport, counting in the SLC22A12 genetic material encoding URAT1, incline persons to high urate levels. Extra jeopardy aspects for hyperuricemia are age, sex, nutritional intake of purine-rich food, alcohol consumption, use of many drugs, such as diuretics and aspirin, and certain diseases, counting renal failure, metabolic syndrome, hypertension, and obesity [28].

Some of the parts of the SLC22 family, globally formed here with the classical denomination of OATs, can carry a broad range of anionic endogenous metabolites and xenobiotic molecules, including many drugs and so, they have an important impact on pharmacokinetics. Most OATs are very expressed in the human liver and/or kidney, and at inferior levels in the brain, prostate, testis, and placenta.

OAT2 (SLC22A7), OAT1 (SLC22A6), and OAT3 (SLC22A8) are positioned at the basolateral membrane of the renal proximal tubular cells, where they are important for the liberation of drugs and toxins for next elimination into the urine. In dissimilarity, OAT4 (SLC22A11), OAT10 (SLC22A13), and Urate Transporter 1 (URAT1) (SLC22A12) expressed at the apical membrane of the proximal tubular cells and used for reabsorption of matters from the tubular fluid. OAT5 (SLC22A10) OAT2 and OAT7 (SLC22A9) were placed at the sinusoidal membrane of liver cells and employed in liver detoxification actions [29].

Man sodium-dependent phosphate co-transporter type 1 gene (NPT1/SLC17A1) is familiar as the first urate emission transporter that functions regularly in the human being kidney. Recent genome-wide association studies proposed that widespread variants of the human sodium-dependent phosphate co-transporter type 1 gene (NPT1/SLC17A1) impact serum uric acid showed that; NPT1 is a renal urate exporter in human beings, and that its frequent variant I269T exhibit considerably augmented urate transfer [30].

A study done by Jutabha P suggested that; the genetic dissimilarity of NPT4 participates in inter-individual variations of anionic drugs such as diuretics as well as particular endogenous organic anions such as urate [31].

Togawa N, et al. suggested that; A Na^+ phosphate co-transporter homologue (SLC17A4 protein) is the probable taking part of an NPT homologue in urate extrusion from the intestinal duct [32]. A study done by Nakayama A, et al, revealed that; A missense variant of MCT9 (K258T), rs2242206, considerably augmented the jeopardy of renal excess gout, so, rs2242206 is a frequent missense variant and is exposed to have gone with ROL gout, representing that rs2242206 links to reduced intestinal urate excretion and not reduced renal urate excretion [33].

Cheepala SB, et al. suggest that; in platelets, ABCC4 helps with PDEs in controlling platelet cAMP, and thus platelet aggregation response in mice and man [34].

The voltage-gated KCNQ1 (KvLQT1, Kv7.1) potassium channel functions a central role in forming the cardiac action potential as well as in regulating the water and salt homeostasis in several epithelial tissues [35].

Peptide Transporter 2 (PEPT2)-PDZK1 interface has a physiologically significant responsibility in both oligopeptide management as well as peptide-like drug transport in the human kidney [36].

NIPAL1 (NIPA-like domain containing 1), encoding a magnesium entry transporter, as an islet-enriched genetic material. In changeable magnesium levels, *NIPAL1* knockdown reduced both basal insulin release and total insulin; in

difference, it's more expression augmented sum insulin. While the expression, distribution, and magnesium sensitivity of *NIPAL1* in α-TC6 glucagonoma cells (a pancreatic α-cell line) were alike to the notes in Min6-K8 cells, no influence was observed on glucagon discharge in α-TC6 cells. These outcomes propose that *NIPAL1* expression is controlled by extracellular magnesium and that down-regulation of this carrier reduces glucose-stimulated insulin discharge and intracellular insulin, predominantly in conditions of hypomagnesemia [37].

As emitted mature IL-1 beta is recognized after apoptosis, this cytokine, when formed endogenously, functions a part in cell death. Hypoxia-induced apoptosis is kept by either the IL-1 Receptor antagonist (IL-1Ra) or by antibodies deactivation to IL-1 or its type 1 receptor. IL-1Ra moreover suppresses apoptosis resulting from trophic factor deprivation in primary neurons, as well as by tumour necrosis factor-alpha in fibroblasts. Additionally, throughout the G1/S phase seize, mature IL-1 beta provokes apoptosis through a pathway independent of CrmA-sensitive gene action. Also show that Ice, when expressed in COS cells, needs the co-expression of pro-IL-1 beta for the initiation of apoptosis, which is suppressed by IL-1Ra. fascinatingly, mature IL-1 beta has anti-apoptotic action when added exogenously previous to the beginning of hypoxia, which is caused in part by its capacity to down-regulate the IL-1 receptor. Pro-IL-1 beta is a substrate of ICE related to cell death and relying on the sequential cellular commitment to apoptosis, mature IL-1 beta may be purpose as a positive or negative moderator of apoptosis [38].

IL-8RB may function as a dynamic part at the beginning of neutrophil migration remote from the spot of inflammation, where the level of IL-8 is at the picomolar concentration. Following down-modulation by 119 nM IL-8, the expression of IL-8RA fully improved within 1.5 h, while the upturn rate of IL-8RB expression was slow and never attained more than 40% of the control level throughout 3 h culture duration. The quick re-expression of IL-8RA proposes that the little affinity IL-8RA may have a more active task in mediating IL-8 signal at the place of inflammation, where the level of IL-8 is high [39].

IL-12 was recognized to influence thymic T-cell choice, study done by Li L, et al., showed that; activation of thymocytes with IL-12 only also did not cause the thymocyte proliferative response in vitro. IL-12, but, gave a potent synergistic outcome to increase the IL-7 or IL-2 enhanced thymocyte proliferative response [40].

The y chain of the interleukin-2 (IL-2) receptor is communal with the functional IL-4 receptor and is causatively linked to X-linked severe joint immunodeficiency (XSCID), which is attributed to a profound T-cell defect. Investigations with monoclonal antibodies specific for the IL-2 receptor y chain showed that the y chain shares in the functional high-affinity receptor complexes for IL-7 that are concerned with the discrimination of T and B cells. The contribution of the y subunit in more than one receptor may allow the clarification of the methods of XSCID progress and lymphocyte discrimination [41].

Macrophages (Mϕ) have a vital function as effector cells in immunity to intracellular pathogens. Mϕ-1 polarized in the existence of granulocyte-Mϕ colony-stimulating factor upheld type 1 immunity, Mϕ-2 polarized with Mϕ colony-stimulating factor subverted type 1 immunity and thus may encourage immune escape and chronic infection. Mϕ-1 secreted high levels of IL-23 (p40/p19). In difference, activated Mϕ-2 formed neither IL-23 nor IL-12 but mostly secreted IL-10. Mϕ-1 required IFN-γ as a secondary signal to provoke IL-12p35 gene transcription and IL-12 secretion. Stimulated dendritic cells formed both IL-12 and IL-23, but different Mϕ-1 they faintly decreased their IL-23 discharge after adding of IFN-γ [42].

IL-1beta and TNF-alpha unconnectedly and synergistically lower human myocardial role. Sphingosine a lipid arbitrator that has significant functions in varied cellular roles such as cell proliferation, differentiation, and migration is probably shared in the TNF-alpha and IL-1beta signal causing human myocardial functional suppression [43,44].

Chemokines, in addition to their chemotactic features, work upon resident cells inside tissue and arbitrate other cellular roles. Leukocyte chemotaxis has been revealed to participate in ischemic injury. As the chemoattractant features of CCL2 have been recognized, the defensive impacts of this chemokine propose a unique function for CCL2 in myocardial ischemia/reperfusion injury [45].

As Interleukin (IL)-1β performs a key role in fighting the attacking microbe as part of the natural immune response, its dysregulation is accountable for several autoinflammatory disorders. Huge IL-1β stimulating platforms, identified as inflammasomes, can bring together in response to the finding of endogenous host and pathogen-associated danger molecules. Configuration of these protein complexes outcomes in the autocatalysis and stimulation of caspase-1, which

processes precursor IL-1β into its biologically dynamic structure. The advantages of the nucleotide-binding domain (NOD)-like receptor protein 3 (NLRP3) inflammasome purpose in the host immunity against attacking microbes (the good), the comparatively uncommon genetic inflammasome-pathway that lead to extreme IL-1β stimulation and several associated diseases (the bad) and the experimental and clinical confirmation for unwarranted inflammasome action sharing to frequent pathologies influencing millions of people, such as cancer and diabetes.

Through current years there has been rising attention in the inflammatory module of the disease, and in exacting in the task of IL-1β. Indeed, IL-1β is suggested to take part in a significant function in the loss of β cell mass in the course of type 2 diabetes, and a present theory proposes that the relative equilibrium between IL-1β and endogenous IL-1Ra controls pancreatic islet inflammation related to the disease. Extraordinarily, a new clinical trial holds the concept that IL-1β is certainly a chief participant in type 2 diabetes, as patients getting IL-1β antagonists featured enhanced glycaemic control and β cell mass. Remarkably, diabetic markers such as augmented concentrations of saturated fatty acids and islet-derived amyloid polypeptide documented as capable of activating the NLRP3 inflammasome, and NLRP3- and ASC-deficient mice fed a high-fat food show better insulin sensitivity when matched to control mice. More experimental records propose that the NLRP3 inflammasome is a vital controller of adipocyte differentiation and insulin sensitivity. Adipocytes rendered more metabolically dynamic and insulin-sensitive upon NLRP3 inflammasome suppression in murine forms of obesity. The NLRP3 inflammasome is capable to sense obesity-associated danger signals and share to the expansion of inflammation and insulin resistance. Investigations propose that IL-1, like the other main proinflammatory cytokine TNF, is often linked with tumour promotion. An assessment of many clinical trials by recombinant IL-1β or IL-1α confirmed that neither had any considerable therapeutic advantage when used alone against renal cell carcinoma, ovarian cancer, or melanoma, and the toxicity linked with IL-1 administration is probable to outweigh any possible advantages [46].

In certain, TXNIP, a chief inflammasome mediator, induces gathering of the NLRP3 inflammasome, leading to caspase-1-mediated reduction of the heterochromatin-causing epigenetic repressor KAP1/TRIM28 in a sub-population of cells. As an outcome, merely TXNIP^{hi}KAP1^{lo} cells, that is, in a primed/pyrolytic state, revolve expression of the replication/lytic/reactivation switch protein on to involve in the replicative phase. A study by Burton EM showed that; Epstein-Barr Virus (EBV) dovetails its evasion plan to a key cellular danger-sensing method, signify that transcription controlled by KAP1 profusion away from canonical control through its posttranslational change, mechanistically connect diabetes, which regularly stimulates the NLRP3 inflammasome, to deregulation of a tumour virus, and shows that B lymphocytes from NOMID (Neonatal Onset Multisystem Inflammatory Disease) patients who have NLRP3 mutations and face hyperactive innate responses are imperfect in regulating a herpesvirus [47].

Lately, it suggested that the mitochondria, and not NADPH oxidase action, are the source of ROS needed for NLRP3 stimulation. In support of this, it was documented that monocytes from patients who carry missense mutations in TNFR1 and face an auto-inflammatory condition named TNF-Receptor-Associated Periodic Syndrome (TRAPS) show augmented mitochondrial respiratory ability and ROS production matched to normal monocytes, causing more cytokine, including IL-1β, production.

As well as its fundamental responsibility in the pathogenesis of auto-inflammatory disorders, the NLRP3 inflammasome has emerged lately as an unforeseen sensor for stress and metabolic danger. Certainly, it is concerned with the expansion of most important diseases such as gout, which is a sterilized inflammatory disease attributed to Monosodium Urate (MSU) crystal accumulation in a variety of tissues. The prototypical clinical feature is acute monoarthritis, where MSU crystals share in the joint, activating an acute local inflammatory reaction. MSU crystals showed to specifically stimulate the NLRP3 inflammasome, both *in vivo* and *in vitro*. Furthermore, the NLRP3 inflammasome was proposed as instrumental in the inflammatory part of the disease and its related brain tissue damage [46].

Most hyperuricaemic patients never build up clinical features of gout, despite the information that, in many studies, advanced imaging identified Monosodium Urate (MSU) crystal articular tissue accumulates in □25% or more such subjects. In difference to the understanding of ecological and genetic exposures regulating urate load (reflected by serum urate level), comparatively little is known about risk aspects controlling the development of gouty arthritis in human beings, counting through the main checkpoints of MSU crystal accumulation and NOD-like Receptor Family Pyrin domain containing 3 (NLRP3)-inflammasome-mediated innate immune reaction. In this issue, Chang, et al., give new insight into this feature of gouty pathogenesis, by recognizing a locus holding the gene PPARGC1B as a

risk factor for gout. Taken jointly, the results of Chang, et al. recognize PPARGC1B as one of many inducible nodes, counting PPARγ and AMPK, in the complicated control network for damping NLRP3 inflammasome stimulation and the inflammatory arthritis phenotype in gout PPARGC1B was earlier well-known to uphold anti-inflammatory macrophage differentiation and inhibit expression of multiple cytokines [48]. Since decreased mitochondrial DNA copy number is connected with gout, likely, systematically associated alterations on PPARGC1B, PPARγ and AMPK expression and action are aspects linking mitochondrial dysfunction and gout. Certainly, in some molecular inflammatory disease formS, NLRP3 inflammasome stimulation is potently controlled by changed mitochondrial tasks [49].

Stimulation of Toll-Like Receptor (TLR) signalling by microbial signatures is important to the initiation of immune reactions. Such reactions need tight control. RP105 is a TLR homolog, thought to be principally B-cell-specific, which has no signalling domain. RP105 expression is broad, straight mirroring that of TLR4 on antigen-presenting cells. Show that RP105 is a precise suppressor of TLR4 signalling in HEK293 cells, a purpose conferred by its extracellular domain. Particularly, RP105 and its assistant molecule, MD-1, reacted directly with the TLR4 signalling complex, suppressing its ability to connect microbial ligand. Lastly, show that RP105 controls TLR4 signalling in dendritic cells, in addition to endotoxin responses *in vivo*. Thus, these outcomes recognize RP105 as a physiological negative controller of TLR4 responses [50]. RP105 controls the antigen-presenting cell role and Treg progress, which provoked reduction of the cell-mediated immune responses and, as an outcome, inhibited the progress of collagen-induced arthritis [51].

CD14 expression on macrophage and sCD14 levels in the culture supernatants were significantly decreased after Monosodium Urate (MSU) treatment. But, there was no significance in the levels of membrane CD14 and sCD14 in fit volunteers' PBMC stimulated by LPS. Taken together, these suggest that CD14 might play an important role in the self-remission of gout [52].

Mutated T60 CARD8 exerted a dominant-negative influence by its ability to connect to and from oligomers with un-mutated T60 or T48 CARD8 that hindered their linking to NLRP3. Lastly, inflammasome stimulation investigations discovered that intact but not mutated CARD8 stopped NLRP3 deubiquitination and serine dephosphorylation [53].

Hyperuricemia is an inflammatory disorder that is attributed to the increased synthesis of Interleukin-1β (IL-1β) activated by Monosodium Urate (MSU) crystals. But, some hyperuricemia patients, even hyperuricaemic patients with tophi in the joints, never experience gout episodes, which points to the pathogenic pathways other than Monosodium Urate (MSU) take part in secretion IL-1β in the pathogenesis of acute gouty arthritis. A study done by Tao JH, et al., revealed that; ATP enhances the pathogenesis of gouty arthritis through rising secretion of IL-1 β, and its receptor (P2X7R) function connected single nucleotide polymorphisms associated with gouty arthritis, which points to that ATP-P2X7R signalling pathway a significant controller task in the pathogenesis of gout [54].

Detection of a mutation in the *EGF* gene in isolated autosomal recessive renal hypomagnesemia recognized a magnesiotropic hormone critical for whole body Mg^{2+} equilibrium. The mutation guides to weakening basolateral organization of pro-EGF. As a result, the renal EGFR is poorly activated, ensuing in inadequate activation of the epithelial Mg^{2+} channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6) and so Mg^{2+} loss. Moreover, explain that colorectal cancer patients treated with cetuximab, an antagonist of the EGFR, expand hypomagnesemia, confirming the significance of EGF in preserving Mg^{2+} equilibrium [55]. Zeng C, et al. suggest that; serum Mg is inversely connected with HU. This connection is still convincing for the male subgroup, but not for the female subgroup [56].

A study done by Chang CH, et al. discovered that; pulmonary TB has a sex-reliant influence, with enhanced EGFR-TKI response and 1-year PFS in females, but poorer in male patients [57].

RNA editing describes a molecular route by which a nucleotide sequence is altered in the RNA transcript and outcomes in an amino acid alteration in the recorded message from that particular gene.

Mammalian RNA editing is hereditarily and biochemically categorized into two groups, insertion-deletional and substitutional. Substitutional RNA editing is restricted to mammals, again with two types accounted, adenosine to inosine and cytosine to uracil (C to U). Apobec-1 RNA itself is a goal for posttranscriptional control by the RNA linking protein T-cell Intracellular Antigen-1 (TIA-1) and RNA connecting protein that links AU-rich elements in the

3′UTR and works primarily to suppress translation. TIA-1 control of Apobec-1 mRNA expression showed at least partly the outcome of changed mRNA decay, possibly reflecting the existence of an AUUUA motif inside a minimal consensus place in the 3′UTR of Apobec-1 [58].

The Hepatocyte Nuclear Factor four-Gamma (HNF4G), is up-regulated and works as an oncoprotein in bladder cancer. Wang J, et al., noticed that; HNF4G expression was high in lung cancer tissues as matched to neighbouring normal lung tissues, pointing to that HNF4G exerts an oncogenic function in lung cancer by enhancing cell proliferation and that HNF4G expression is a possible prognosis aspect for lung cancer [59].

TRIM46 works an informative function in the first polarization of neuronal cells. TRIM46 is especially restricted to the freshly specified axon and, at later phases, partially overlaps with the axon early segment (AIS). TRIM46 particularly shapes intimately spaced parallel microtubule bundles positioned with their plus-end out. With no TRIM46, every neurite owns a dendrite-like varied microtubule arrangement ensuing in Tau miscategorization and changed load movement [60].

The low-density lipoprotein receptor-associated protein 2 is a multipurpose cell-surface receptor presented by the embryonic neuroepithelium. Loss of LRP2 in the rising murine Central Nervous System (CNS) induces damaged obstruction of the rostral neural tube at embryonic phase (E) 9.0. Same neural tube faults (NTDs) have formerly been attributed to harmed folate metabolism in mice. A study done by Kur E, et al. showed that; LRP2 is vital for cellular folate uptake in the mounting neural tube, a critical point for right neural tube closure [61]. A study done by Sadik B, et al. showed that; Consanguine wedding is a possible risk factor for NTDs progress and is common in Sudan. Deprived folate intake and motherly febrile illnesses are risk aspects and extra larger studies would better discover malaria as a risk factor recommended [62].

Glucokinase (GCK) is accountable for preserving glucose homeostasis in the human being body. Dysfunction of GCK leads to hyperinsulinemia, hypertriglyceridemia, and type 2 diabetes. In the liver, GCK is controlled by interaction with the Glucokinase Controller Protein (GKRP), a 68 kDa polypeptide that serves as a competitive suppressor of glucose linking to GCK [63].

A study done by Kumar S showed that; ADRB3 C190T may also be concerned with the complicated pathophysiology of Coronary Artery Disease (CAD) [64]. A potent down-regulation of ADH1B expression in CAFs *in-situ* and culture along with raised expression of the tumour growth-enhancing inflammatory cytokine IL-6 [65].

ALDH2 reduces the progress of Hypoxia-induced Pulmonary Hypertension (HPH) [66]. The best-investigated and most hopeful cytokine to date is IL-6, in exacting for expansion of hypoxia-induced pulmonary hypertension [67].

The enzyme Catechol-O-Methyl Transferase (COMT), recognized in the 1950s, is concerned with the catabolism of monoamines that are affected by psychotropic medicines, counting neuroleptics and antidepressants [68].

Shortage in Monoamine Oxidase A (MAOA), an enzyme that breakdowns serotonin and norepinephrine, has lately been shown related to aggressive behaviour in men of a Dutch family [69].

The type II cGMP-dependent protein kinase (cGK) works as an essential factor in the control of intestinal fluid equilibrium in man [70].

Transcriptional profiling of platelets discovered that WD-40 Repeat Domain 1 (WDR1), a promoter of actin-depolymerizing factor action, is down-regulated in platelet messenger RNA (mRNA) from subjects with a hyper-reactive platelet phenotype. WDR1 knock-down (KD) in MEG-01 cells augmented adhesion and dispersion in both the basal and stimulated states, amplified F-actin content, and raised the basal intracellular calcium level. WDR1 acting a central role in inhibiting platelet action, where it changes the actin cytoskeleton activities, and down-regulation of WDR1 may take part in the platelet-mediated pathogenesis of cardiovascular disease [71].

High ALPK1 expression reduced URAT1 expression. ALPK1 might stop the impact of urate reuptake by SLC22A12 and seem negatively related to gout. ALPK1 is a possible suppressor of URAT1 protein expression [72].

CARMIL1 is homo-dimerized by itself like Acanthamoeba CARMIL acts. The phylogenetic analysis discovered conserved CARMIL-encoding genes in a broad range of metazoans, counting arthropods and amoebae. CARMIL1 its roles in lamellipodia in regulation actin gathering through influences on Trio and Rac1 [73].

A study done by Ait-Lounis A showed that; Rfx3 is necessary for the differentiation and task of mature beta-cells and controls the beta-cell supporter of the glucokinase gene [74].

Changes in the response to estrogen are linked with various hormone-dependent diseases, such as breast cancer, endometrial cancer, cardiovascular disease, and osteoporosis. Breast Carcinoma Augmented Sequence-3 (BCAS3) is a gene of the unidentified role that is positioned to 17q23, a chromosomal region augmented in about 20% of primary breast tumours, as evaluated by comparative genomic hybridization. Lately, showed that BCAS3 is an estrogen-inducible gene since ER is recruited to a control region of BCAS3 through a half ERE (1/2 ERE) [75].

Modifications happening at the molecular level that may change the ruling of glutamate and its receptors are potentially vital for an understanding of the pathophysiology of schizophrenia. A study done by Drummond JB, et al. showed that; CNIH-1, CNIH-2, and CNIH-3 are transcriptionally up-regulated in DLPFC in schizophrenia. These data propose a relation between CNIH expression, AMPAR dysregulation, and the pathophysiology of schizophrenia [76].

Current investigations have recognized SNP rs7903456 of FAM35A related to gout. Since of the intimate relations between hyperuricemia and gout. A study done showed that the T allele of rs7903456 could boost the uric acid concentration by ~10 mmol/L on average after regulating many biochemical and clinical parameters [77].

A study was done by Kwon YJ, et al., discovered GML-CYP11B1 rs3819496, MYL2-CUX2 rs12229654, and JAG1 rs1887320 considerably related to reduced risk of hypertension in participants with sodium intake ≥ 2 g/day. Even though MYL2-CUX2 rs12229654 and its relationship with hypertension were first documented in this study, a well-built connection of genetic variants of MYL2-CUX2 with high-density lipoprotein cholesterol was revealed in a Korean GWAS meta-analysis, and it replicated in a BioBank Japan GWAS, Health 2, and Shanghai Jiao Tong University cohort. A further study done in Korea identified that rs1229654 was also linked with dyslipidemia and diabetes. Metabolic change owing to rs1229654 might lead to the progress of hypertension [78].

Malaria and Gout Related Genes

A study done by Cressman AM, et al., showed that; considerably reduced hepatic expression of *Abcc2*, *Abcg2*, and *Abcb11* and notably augmented expression of *Abcb1b*, *Abcc1*, and *Abcc3* seen in malaria-infected dams ($p<0.05$) in contrast with uninfected controls. Expression of *Abcb1a* and *Abcg2* extensively diminished in the fetal liver of infected dams, while levels of *Abcb1b* amplified ($p<0.05$). Motherly and fetal hepatic expression of *Cyp3a11* was considerably down-regulated in the malaria group ($p<0.05$). Jointly, malaria-induced changes in expression of transporters and drug-metabolizing enzymes in maternal and fetal tissues may change the disposition of endogenous and therapeutic substrates, potentially influencing maternal and fetal outcomes [79].

A study was done by Meireles P, et al., suggested that; that glucose is an essential modulator of hepatic infection by the rodent malaria parasite *Plasmodium berghei* and that glucose uptake by the GLUT1 transporter is particularly promoted in *P. berghei*-infected cells. Further show that ATP levels of cells containing rising parasites reduced, which identified to augment membrane GLUT1 activity. Also, GLUT1 molecules translocated to the membrane of the hepatic cell, rising glucose uptake at later phases of infection. Chemical suppression of GLUT1 activity causes a diminish in glucose uptake and the resulting impairment of hepatic infection, both *in vitro* and *in vivo*. Alterations in GLUT1 conformation and cellular localization appear part of the adaptive host response to keep enough cellular nutrition and energy levels, ensuring host cell endurance and enhancing *P. berghei* hepatic development [80]. Suppression of glycolysis or removal of GLUT1 stops M1 polarization [81]. M1 macrophages are mostly concerned with pro-inflammatory reactions [82].

A study done by Asif AR suggested that; RT-PCR did not expose the expression of human OAT1 and OAT2, but OAT3 and OAT4 mRNAs were observed in both NCI-H295R cells and human being adrenal tissue. When man OAT3 (hOAT3) and hOAT4 were expressed in Xenopus laevis oocytes, only hOAT3 exposed cortisol uptake in surplus of that of water-injected control oocytes [83].

A study done by Vandermosten L suggested that; in malaria, adrenal hormones do not defend against lung and liver inflammation. But, they prevent extreme systemic and brain inflammation and severe hypoglycemia, so taking part intolerance [84]. The NCI-H295R cells secrete many steroids including cortisol, corticosterone, aldosterone, estrogens, and adrenal androgens. As IL-6 augments the expression of the steroidogenic enzymes required for the production

of corticosterone, aldosterone, and adrenal androgens, IL-6 may also boost the liberate of these hormones from the NCI-H295R cells [85].

Nussler A, et al., tested the ability of murine recombinant Tumor Necrosis Factor (rmTNF) to provoke an inhibitory impact at the hepatic stage on malaria produced by *Plasmodium yoelii* sporozoites. When administered three times, 1.0 micrograms of rmTNF were recognized to keep 78% of mice against a sporozoite challenge. In comparison, whatever the dose and the schedule of administration, no suppression was noticed when purified hepatocyte cultures were infected with *P. yoelii*. The adding of non-parenchymal hepatic cells to hepatocyte cultures reinstated the ability of TNF to modulate hepatic stage progress, causing up to 44% inhibition. Antibodies to interleukin 6 reversed the anti-parasite action in the co-culture system [86].

Adding recombinant interleukin-6 (IL-6) to *Plasmodium yoelii* hepatic cultures resulted in a precise dose-dependent suppression of parasite progress. Time-course experiments suggested that, without any direct influence on free sporozoites, IL-6 exerts its action by both the early phase of infection and throughout the later maturation of the schizonts [87].

Through its intrahepatic reproduction, the *Plasmodium yoelii* induces a decrease in IL-6 production. IL-6 mRNA was not detected in the livers of infected mice throughout the progress of either hepatic or blood-stage parasites while IL-6 activity was found in the sera throughout both stages [88].

A study done by Menard, et al., suggested that; a gene coding for a novel putative transporter, NPT1, plays a crucial role in the progress of *Plasmodium berghei* gametocytes [89]. Also, a further study suggested that NPT1 controls gametocytogenesis and sexual differentiation [90].

A study done by Jutabha P, et al., suggested that an orphan transporter hNPT4 (human sodium phosphate transporter 4; SLC17A3) was a multi-specific organic anion efflux transporter presented in the liver and kidneys. Human sodium phosphate transporter 4; positioned at the apical side of renal tubules and ruled as a voltage-driven urate transporter [91].

NHERF3 is a cytoskeletal protein placed in renal tubular epithelial cells that interacts with several uric acid transporter proteins to regulate uric acid transport. It interacts with several gene products, counting *ABCG2*, *URAT1, SLC17A1*, and *SLC17A3*. Preceding research pointed to that *NHERF3* works a chief controller task in these membrane transporters. These genes can influence the serum uric acid reabsorption by the renal tubules by control of *NHERF3* (PDZK1), which causes hyperuricemia or gout. Interleukin (IL)-37 is an immune-modulating agent known through computational sequence analysis in 2000, and it is the seventh member of the IL-1 family (initially designated IL-1F7). High levels of IL-1b, IL-6, IL-10, Tumor Necrosis Factor (TNF)-a, and Transforming Growth Factor (TGF)-b1 have formerly been recognized in specimens from patients with Gouty Arthritis (GA). Current studies have set up that IL-37 has inhibitory impacts on a variety of inflammatory factors, counting Toll-Like Receptor (TLR) ligands, IL-1b, TNF, and IL-12 combined with IL-1b. It plays a vital role in uric acid transport by altering the expression of PDZK1 via molecular signalling pathways [92].

IL-37 is a lately revealed cytokine in the IL-1 family exerting wide protective influences on inflammatory diseases, autoimmune diseases, and cancer. Immune and non-immune cells produce the IL-37 precursor upon pro-inflammatory stimulus. Intracellularly, caspase-1 cleaves and activates IL-37, and its established form links to Smad3; this complex translocates into the nucleus where it inhibits cytokine synthesis, so dipping inflammation. Extracellularly, IL-37 forms a complex with IL-18Rα and IL-1R8 (formerly TIR8 or SIGIRR) that transduces anti-inflammatory signals by inhibition of NF-κB and MAPK and stimulation of Mer-PTEN-DOK pathways. Throughout inflammation, IL-37 inhibits the expression of many pro-inflammatory cytokines in favour of the expression of the anti-inflammatory ones by the control of macrophage polarization, lipid metabolism, inflammasome function, TSLP production, and miRNAs role. Furthermore, IL-37 not merely controls the natural and adaptive immunity, but also promotes ageing-related immune-senescence, recombinant IL-37 decreased the synthesis of IL-8 and reactive oxygen species [93]. Uncommon variants of the gene encoding IL-37 have been recognized that result in loss of the cytokine's anti-inflammatory influences and confer a predisposition to gout [94].

Analysis of the NPT homolog SLC17A4 revealed that this transporter has the same character as NPT1 [95].

Interleukin (IL)-1β is a cytokine produced as a part of the natural immune response to *Plasmodium falciparum*. Kids

with SMA had considerably lesser IL-1β levels and non-significant elevations in both IL-1 receptor antagonist (Ra) and the IL-1Ra: IL-1β ratio contrasted to the non-SMA group, that difference in IL-1β promoter setting vulnerability to SMA and functional alterations in circulating IL-1β levels [96].

A study done by Brown H established that; IL-1beta was missing from the typical brain but identified in CM and other cerebral infections [97].

A study done by Moormann AM showed that; TNF-alpha and IL-8 were released by maternally derived hemozoin-laden placental macrophages. Augmented TNF-alpha expression linked with amplified placental malaria pigment concentrations [98].

A study done by Anusree Mahanta, et al., suggested that; IL-8-251T/A augmented the chance of complicated malaria [99].

Lourembam SD, et al, suggested that; age is seen as a factor with high IL-8 levels in young *P. falciparum* positive participants as contrasted to older person [100].

IL-12 serves a significant role in the specific immune response to malaria. Though correlation with disease severity has been verified, the concentrations of IL-12 have been set up paradoxically lesser in African children with severe malaria, probably owing to suppression after phagocytosis of malaria pigment or IL-10 induction. though the differences were little, we found IL-12 high in cases of severe malaria, with slight significant dissimilarity between subsets of severe malaria. The causes for the lack of IL-1β increase and the small TNF-α and IL-12 elevations consequence of down-regulation by IL-10 [101].

IL-12 and IL-23 are connected pro-inflammatory cytokines that take part in both the p40 subunit and the IL-12Rβ1 receptor subunit. IL-12 signals by a receptor including IL-12Rβ1 and IL-12Rβ2 and is a strong inducer of IFN-γ which mediates both removals of parasitemia and immunopathology in infections with Plasmodium parasites. IL-23 signalling (through its receptor, comprising IL-12Rβ1 and IL-23R) improves transcription of *RORC* which encodes *RORγ*, a transcription factor concerned in the release of IL-17 [102]. A study done by Ishida H, et al. revealed that; IL-23 and IL-17 are not concerned with ECM progress [103].

Up-regulation of *RANTES/CCL5, IP-10/CCL3*, and *CCR2* connected with leukocyte move to the brain and augmented expression of *MCP-1/CCL2, IP-10/CCL3*, and *CCR5* with white blood cells migrate to the lung [104].

A study done by Reimer T, et al., showed that; the function of *Nlrp3* in experimental cerebral malaria is free of the inflammasome and the IL-1 receptor pathway [105].

A study done by Barboza R, et al. showed that; that stimulation of the innate immune system by parasites leads to PM due to limited inflammation. *TLR4* stimulation is the major pathway concerned in the inflammatory course in the placental tissue as the lack of functional *TLR4* in mice leads to a diminish in the pro-inflammatory responses, which resulted in an improved pregnancy outcome [106]. Malarial Prx produces IgE-mediated protection *via.* FcϵRI on mast cells and natural immunity by *TLR4* with *MyD88* and *MD-2* [107].

A study done by Wenisch C, et al., analyzed Serum *sCD14*, Tumour Necrosis Factor-alpha (TNF-alpha), IL-6, and endotoxin in patients with complicated malaria showed that; Malaria patients with renal failure had higher levels than patients without renal failure. A noteworthy correlation between *sCD14* and IL-6 (r=0.756) and TNF (r=0.822) existed, no link between *sCD14* and serum endotoxin and indices of clinical disease severity (parasitemia, fever, parasite, or fever clearance time) seen [108].

It is now obvious that the method core the "malaria toxin hypothesis" includes a harmful activation of natural immunity cells by *Plasmodium*-derived components, recognized as Pathogen-Associated Molecular Patterns (PAMPs) and the Danger-Associated Molecular Patterns (DAMPs), which are endogenous constituents produced from stressed, injured or dying host cells. The extreme activation of non-specific immune cells leads to a cytokine storm with unfavourable impacts on the host.

Certainly, the extreme activation of the innate immune cells and the resultant cytokine storm are accountable for the first signs and symptoms of malaria and arbitrate the severe forms of the disease. Different studies account for high levels of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, TNFα, and IL-8 as well as the A Proliferation-

Inducing Ligand (APRIL) in plasma or sera from symptomatic patients infected with *P. vivax*.

As well, polymorphisms in cytokine genes relate to *P. vivax* malaria vulnerability. Unexpectedly, IL-10, an anti-inflammatory cytokine, is consistently expressed in very high levels in these symptomatic patients.

One study assessed the relationship of SNPs in inflammasome-related genes (ie, *NLRP1, NLRP3, AIM2, CARD8, IL-1β, IL18*, and *MEFV*) with the clinical outcome of *P. vivax* malaria [109].

One of the earliest and conserved DAMPs is extracellular ATP that exerts its phylogistic action chiefly *via.* stimulation of the P2X7 receptor (P2X7R).

A recent study by Machado de Salles and colleagues, showed a key function of P2X7R in the response against the parasite *Plasmodium chabaudi*, showing that P2X7R null mice are more vulnerable to malaria infection owing to modified Th1 differentiation. Through malaria blood-stage, P2X7R on CD4+ lymphocytes stimulated enhancing the progress of protective immunity against *Plasmodium chabaudi via.* t-bet expression and INFγ/ IL 2 secretion [110].

Drew, et al. formerly suggested that *PfMSP-8* may purpose in the founding of the parasitophorous vacuole in early-ring-stage parasites. In that study, *PfMSP-8* expression was detected on ring-stage parasites but not on the surface of merozoites by immunofluorescent assay applying an antibody increased against the C-terminal EGF-like domains. Detect *MSP-8* on *P. falciparum* and *P. yoelii* merozoites but merely with antibodies with specificities lying exterior of the EGF-like domains. It is probable that the EGF-like domains of *MSP-8* are not exposed or are merely transiently exposed on merozoites before invasion [111].

The liver is a complicated gland, composed of well-organized lobules where liver cells express different metabolic functions connected to their Zonal site (Z). Liver cells of a particular zone do express precise sets of genes reflective of their differential roles linked to glucose metabolism. As such, periportal Z1 is concerned with gluconeogenesis throughout homeostasis as Z3 produces energy by glycolysis. Glucokinase (GK) is a central cytoplasmic enzyme of glycolysis, catalyzing the first step of altering glucose to glucose-6-phosphate. In a gluconeogenic state, i.e. Z1, GK is sequestered away from the cytoplasm, being suppressed by its regulatory protein (GKRP) and assumes a nuclear localization.

A study done by Yang ASP showed that; intracellular *Pf* progress in the liver is strongly directed by the glucose metabolic condition of exacting hepatocyte subpopulations. The glycolytic style and the exclusive existence of hGS in Z3 hepatocytes are useful for intra-hepatic stages of particular *Pf* strains as reflected by the larger schizont sizes (NF135 and NF175). Also, the anti-diabetic drug metformin efficiently decreases the size of *Pf* liver schizonts. Metformin enhances the linking of hGK to GKRP, resultant in a nuclear localization reminiscence of a Z1/2 phenotype, revealed to result in smaller schizonts [112].

Beta-adrenergic receptor obstruction with propranolol stopped the synthesis of cyclic AMP from immature mouse red blood cells but did not influence the stimulation produced by prostaglandin El [113].

Aldehyde Dehydrogenases (ALDH) is a significant collection of enzymes concerned in the ethanol detoxification course. Aldehyde Dehydrogenase 2 (ALDH2) is plentiful in the liver where it catalyzes the change of acetaldehyde to acetic acid.

The ALDH2*2 mutation substitutes glutamate with a lysine at arrangement 487 which is in the active place, so suppressing enzyme action and resulting in a build-up of destructive aldehydes. This mutation happens naturally in 600 million people of Asian descent and is linked with 'Asian flushing syndrome'. The genomes of malaria parasites in the genus *Plasmodium* do not encode proteins in the ALDH family of proteins, signifying that malaria parasites depend on the host to detoxify aldehydes.

Sadie, et al, assessed the influence of the ALDH2*2 mutation on aldehyde metabolism in mice with malaria. Undomesticated kind mice and mice with the ALDH2*2 mutation were observed throughout infection with *Plasmodium yoelii* for blood aldehyde levels, ALDH enzyme action, and markers of liver injure. Theories about host-parasite interactions and selection pressures for the progress of host defenses as well as the probable to use this biology to build up novel therapeutic plans for malaria presented [114]. PfPKG suppressors could be helpful in the treatment of different stages of malaria [115].

WDR1 is an extremely conserved controller of the actin cytoskeleton in eukaryotes. A new splice variant of *WDR1* revealed, *WDRΔ35,* which deficient's exons 3-5. Overexpression of *WDR1/WDRΔ35* leads to a much reduction in cell migration contrasted to the GFP control [116].

A study was done by Abris Adam Bendes and Petri Kursula, for V-1/myotrophin homologs and the CP-binding and uncapping motif of *CARMIL* proteins between identified Plasmodium transcripts, or for the S100B interaction motif in malaria parasite CPs resulted in no clear hits [117].

Interaction of Malaria Danger Associated Pattern Genes and Cytokines

URAT1 expression in macrophages reduced as uric acid level augmented, which might partly clarify the fact that TNF-alpha, TLR4, and CD11c expression attained saturation point, which in turn led to a diminish their protein concentrations. Uric acid has to start pro-inflammatory influences on macrophages probably by URAT1. [118].

Glucose acts as the main energy substrate and the chief precursor for the production of glycosaminoglycans in chondrocytes. Eased glucose transport signifies the first rate-limiting point in glucose metabolism. IL-1β and TNF-α, and to a minor degree IL-6, speed up facilitated glucose transport as measured by [^{3}H]2-deoxyglucose uptake.

IL-1β produces an amplified expression of glucose transporter (GLUT) 1 mRNA and protein, and GLUT9 mRNA. GLUT3 and GLUT8 mRNA are constitutive expressed in chondrocytes and are not controlled by IL-1β. GLUT9 was identified in the spleen, peripheral leukocytes, and brain [119].

A study was done by Mirdamadi K, et al., set up that treatment of explants with IL-23 declined the mRNA levels of OAT4. Considerably diminished placental mRNA expression of OAT4 was formerly seen in pregnancies complex with preeclampsia, a disorder that is also connected with Th-17 stimulation and augmented levels of IL-6, IL-17, and IL-23. OAT4 was concerned in the uptake of the estriol precursor, 16a-hydroxy-DHEA-S, from the fetal compartment, and measured its main transporter, so, taking part in more than 90% of placental estriol production. Consequently, reduced OAT4 could result in an extra decline in placental estrogen synthesis [120].

In the renal tubule, reabsorption of uric acid from the glomerular filtrate comprises two steps: uptake *via.* the brush-border membrane through the anion transporters *SLC22A12* (also known as urate anion transporter 1 or URAT1) and *SLC22A11* (also well-known as an organic anion transporter 4 or OAT4) and discharge from the cells into systemic circulation across the basolateral membrane through the voltage-sensitive, high-capacity, anion transporter *SLC2A9* (also known as *GLUT9*). *GLUT9* has two splice variants, called *GLUT9a* and *GLUT9b*. Together variants expressed in renal tubular cells: *GLUT9a* in the basolateral membrane and *GLUT9b* in the apical membrane. As *GLUT9* is an electrogenic urate transporter, both variants arbitrate the transport of urate out of the cells owing to the inside-negative membrane potential that encourages function of any transport course concerned in anion clearance from cells. Therefore, *GLUT9a* in the basolateral membrane roles in the renal reabsorption of urate. URAT1 is an anion exchanger that arbitrates the entry of urate into cells joined to the efflux of monovalent organic anions outside the cells; the physiologically related anion in this substitute with urate is lactate. As an outcome, the role of URAT1 in the kidney joined to the functions of *SLC5A8* (also well-known as sodium-coupled monocarboxylate transporter 1 or SMCT1) and *SLC5A12* (SMCT2), together with arbitration Na^{+}-coupled active entrance of lactate from the glomerular filtrate into renal tubular cells, thus give lactate for following exchange with urate *via.* URAT1. This useful coupling is enhanced by the findings that loss of function of both *Slc5a8* and *Slc5a12* in the kidney reduces the capacity of URAT1 to absorb urate, thus leading to augmented excretion of uric acid in urine.

The same phenomenon happens with OAT4, which is also an anion exchanger but with a liking for divalent organic anions such as α-ketoglutarate and succinate. The basolateral membrane of the tubular cells express a high-affinity concentrative uptake system for these dicarboxylates, known as NaDC3 (Na^{+}/dicarboxylate cotransporter 3 or SLC13A3), which builds up dicarboxylates in cells by uptake from blood and these divalent anions act as the transferable substrates for OAT4 in the brush-border membrane [121].

The purine nucleoside carrier *ABCG2* and the voltage-driven carrier *SLC17A1* induce urate secretion at the apical membrane [122].

MYL2 encodes a control light chain related to cardiac myosin β heavy chain and linked with high-density lipoprotein cholesterol metabolism. *CUX2* controls cell-cycle development, and its connection with type 1 diabetes has also been documented. A new locus of gout *rs2188380* of *MYL2-CUX2* may have a probable relationship with BC risk to some extent [123].

A multistage GWAS in the Han Chinese people and have recognized three novel risk loci, 17q23.2 (*BCAS3*), 9p24.2 (*RFX3*), and 11p15.5 (*KCNQ1*), which are most probably linked to development from hyperuricemia to inflammatory gout. Despite this development, several other unknown genes may take part in the configuration of monosodium urate crystals and clinical presentation of acute gout arthritis and chronic tophaceous disease.

A study done by Han L, et al., showed that; the *EGF* SNP rs2298999 is considerably linked with gout in the Han Chinese population and that one familiar *EGF* haplotype connected with this disease. Carrier people of the *EGF* rs2298999 TT genotype in the patient group were less vulnerable to gout than the carriers of the CC genotype. Also, records have shown that SNPs of inflammatory cytokine genes, such as interleukin *(IL)-8* and *IL-12B*, are connected with an augmented risk of gout.

Lately, *EGF* has been ever more believed a pro-inflammatory mediator of several diseases, and Wang, et al. have recognized that the *EGF* rs11568835 G/A polymorphism is associated with amplified jeopardy of rheumatoid arthritis in the Chinese people. Also, a preceding study has documented that gout and rheumatoid arthritis seem to have the same autoimmune mechanisms and that they give a frequent genetic setting. Thus, prove the role of EGF as a pro-inflammatory mediator in gout. Genetic differences in this gene have also been connected to disease vulnerability [124].

Current research has highlighted the significance of the natural immune response in controlling this response, and in particular, the start of acute inflammation. NALP-3 inflammasome stimulation by MSU crystals causes the production of mature interleukin (IL)-1, following discharge of IL-8, leading to recruitment of inflammatory cells within the joint. There are purposeful genetic variants of NALP3 and CARD8, constituents of the inflammasome, concerned with other inflammatory diseases. Signifying that further local or systemic factors can control the inflammatory response to presented intra-articular MSU crystals, cause suppression of the acute gout attack. Factors taking part in the resolution phase of the acute gout attack are less well-known, although putative mechanisms form the generation of anti-inflammatory cytokines such as TGF-Beta, induction of anti-inflammatory signalling pathways such as PPAR, and changes in macrophage differentiation [125].

A study done by Zhou Z, et al., investigated the relationship of candidate genes encoding inflammatory cytokines or engaged in signal induction and established that interleukin-8 (IL-8) gene 251T/A Single Nucleotide Polymorphism (SNP), *IL-12B* gene 1188A/C SNP, IL-23R gene rs7517847 SNP, CC chemokine ligand 2 (CCL2) gene 2518A/G SNP, IL-23R rs10889677, adrenoceptor beta 3 (ADRB3) gene rs4994, Vitamin D Receptor (VDR) gene *rs11568820* and *rs1544410* linked with augmented jeopardy of gout in Chinese male people, while others such as IL-18 gene 137G/C and 607C/A, IL-10 gene 819C/T and 1082G/A were not replicated [126].

Viral IL-10 (vIL-10) takes part in several of the anti-inflammatory features of mouse and human IL-10, but lacks their immuno-stimulatory characters and may so present more immunosuppression. Viral IL-10 has a short half-life.

The i.v. injection of Av(vIL-10) before disease onset late the onset and decreased severity of collagen-induced arthritis, although treatment of established disease was unproductive. The defensive influences were not owing to reduced anti-type II collagen Ab synthesis. Rather, T cells from mice treated with Av(vIL-10) showed a reduced *in vitro* proliferative response to type II collagen, and a delay noticed in up-regulation of synovial mRNA for the pro-inflammatory cytokines IL-2 and IL-1β.

The capacity of vIL-10 to suppress T-cell proliferation in response to CII is reliable with the results of previous research on the influences of vIL-10 on mononuclear cells and is probably to be a result of down-regulation of MHC class II expression on APCs, which can be avoided with anti-CD3 mAb. IL-1β has been shown to worsen CIA, and the anti-arthritogenic impacts of vIL-10 may owe at least in part to its inhibition [127].

Matsuo, et al. accounted that *ABCG2* gene mutations existed in 78.6% of gout patients and that the existence of the

minor alleles of *Q126X* and *Q141K* leads to a significant reduction in the function of *ABCG2*. These dysfunctional genotype combinations cause a more than 75% lessening in the function of *ABCG2*, and noticeably boost the gout danger, Nakayama, et al. reported that a genetic variation of *SLC16A9/MCT9* somewhat amplified the jeopardy of hyperuricemia and gout, and the interleukin-1β level was high in contrast to the reference healthy values [128].

Toll-Like Receptors (TLRs)-2 and -4 and the cytosolic TLR adapter protein myeloid differentiation factor 88 (MyD88) take part in the stimulation of macrophages by MSU crystals. Once activated, TLRs and the IL-1β receptor connect with several intracellular adaptor molecules, counting MyD88, to activate a signalling cascade that stimulates pro-inflammatory transcription factors, such as nuclear factor (NF)-κB, and augments production of pro-inflammatory molecules such as tumour necrosis factor (TNF)-α, IL-6, and IL-8.

Results from *ex vivo* experiments revealed that activation of resident peritoneal macrophages with MSU crystals raised expression of multiple inflammatory cytokines, counting IL-1β, IL-6, and TNF-α. Extra *in vivo* studies proved that reduction of resident macrophages resulted in diminished cytokine synthesis. Moreover, monocytes recruited to places of MSU crystal deposition differentiate into pro-inflammatory M1-like macrophages.

The secretion of TNF-α, IL-1β, IL-6, and IL-8 by monocytes that are activated with MSU crystals raises the expression of multiple adhesion molecules on the surface of endothelial cells, counting E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1. This, in turn, induces to immigration of neutrophils to sites of crystal deposition. Neutrophils are shown to take part in IL-1β synthesis in some inflammatory states, which may also be the case in MSU crystal-induced inflammation. MSU crystals quickly activate tyrosine phosphorylation in neutrophils, leading to the release of superoxide anions essential for *NLRP3* gathering and neutrophil stimulation. Activation of neutrophils in gout is connected with the arrangement of pro-inflammatory neutrophil extracellular traps, which are linked with both autophagy and IL-1β production.

Dendritic cells are antigen-presenting cells that find DAMPs and spread signalling cascades, leading to nuclear translocation of transcription factors and escalation of inflammation. Monosodium urate crystals interact with the surface of dendritic cells via crystal-lipid touch in a way that does not depend on specific cell-surface receptors. MSU crystals keep the lipid surface of dendritic cells, thus perturbing the lipid bilayer and leading to lipid and cholesterol shifting. This lipid arrangement initiates an intracellular signalling cascade that activates spleen tyrosine kinase and leads to following dendritic cell activation.

Mast cells concerned in the first phase response to MSU crystal-induced inflammation anchored in outcomes from the rat peritonitis model. On administration of MSU crystals to the peritoneal cavity, mast cell infiltrates are recognized in the subintimal layer of the peritoneal membrane before monocyte/macrophage and neutrophil entry to the membrane. On stimulation, mast cells discharge factors such as TNF-α, IL-1β, platelet-activating factor, and histamine to control endothelial cell adhesion molecules and enhance inflammatory amplification.

MSU crystal-induced activation of together the classic and the alternative complement pathways takes part in acute gouty inflammation. Complement components including C1q, C1r, and C1s, as well as IgG and IgM, bind to MSU crystals, and the activation course is augmented by the existence of these proteins. MSU arbitrated activation of the classic pathway will also happen in absence of Ig, indicating that MSU crystals can directly start the classic cascade. Activation of the alternative pathway causes the generation of C5a and C5b fragments by a C5 convertase placed on the surface of MSU crystals. These portions work as strong leukocyte chemo-attractants. Also, in response to MSU crystals, the C6-mediated formation of the membrane attack complex has a real role in IL-8 generation and following a neutrophil influx in acute gouty inflammation [129].

It is significant to differentiate between primary gout and secondary gout, the primary gout is commonly known as the direct outcome of under-excretion or overproduction of uric acid; in comparison, secondary gout resulted from predisposing medicines or situations that lead to hyperuricemia [130]. We added figures to show the life cycle of the malaria parasite (Figure 1), biosynthesis of uric acid (Figure 2), and correlation between malaria parasite development and hypoxanthine formation (Figure 3).



Figure 1 Shows the life cycle of the malaria parasite



Figure 2 Biosynthesis of uric acid



Figure 3 Shows the correlation between malaria parasite development and hypoxanthine formation

DISCUSSION

The human inflammatory response in malaria is a crucial issue in the ending of the disease, with inflammation initiating parasite clearance but also taking part in severe malaria pathology. The host inflammatory response is supposed activated by pro-inflammatory molecules that exist in the parasite and/or the ruptured host infected erythrocyte. Some parasite pro-inflammatory molecules are recognized, counting GPI-anchors, a parasite pigment called hemozoin, and parasite DNA.

Uric acid is a physiological by-product of nucleic acid metabolism. The inflammatory features of uric acid are recognized owing to its pathological part in gout, where uric acid crystals shaped in the synovial fluid lead to a strong restricted inflammatory reaction. Uric acid has also been known as a 'danger signal' to change the immune response. Uric acid is discharged from dying cells in high amounts, which would encourage crystallization within the limited environment and inflammation.

Uric acid has lately appeared as a significant moderator of malaria-induced inflammation. *Plasmodium*-infected red blood cells build up hypoxanthine, a precursor for uric acid. Plasmodium cannot produce purines *de novo* and introduces hypoxanthine from the extracellular surroundings as a purine source, which builds up throughout the delayed phases of infection. Introduced hypoxanthine is not broken down into uric acid inside the red blood cells, as xanthine dehydrogenase action, which changes hypoxanthine into uric acid, has not been identified in this cell type or the *Plasmodium* parasite. But, upon red blood cell burst and discharge into the extracellular environment, xanthine dehydrogenase, which is usually present in the blood, and whose expression increased during *Plasmodium* infection, will professionally break it into uric acid. As suggested before, for uric acid play as a 'danger signal', uric acid resulting from degradation of Plasmodium hypoxanthine would enhance crystallization inside the local surroundings and inflammation.

As well as hypoxanthine, *P. falciparum*-infected red blood cells were found to build up uric acid precipitates in the cytosol of the intra-erythrocytic parasite, which discharged to the extracellular environment jointly with daughter parasites upon red blood cell burst. Uric acid precipitates were also found in infected red blood cells freshly isolated from patients with *P. falciparum* and *P. vivax* infections, Also, different rodent malaria species, signifying that uric acid precipitates are a preserved characteristic of *Plasmodium spp.* [5].

The appearance of chloroquine resistance, and a universal shortage of quinine, have resulted in a look for another antimalarial drug directed against falciparum malaria. Allopurinol leads to almost complete suppression of purine biosynthesis of malaria parasites, which may show fatal to the parasites. A study done by Sarma PS, et al., revealed that allopurinol an additive to quinine to causes both faster suppression of *Plasmodium falciparum* and clinical remission than with quinine only [131].

A study done by Prieto-Moure B, et al., showed that; Allopurinol protected ischemic kidneys by a mechanism coupled with downregulation of TNF-α, IL-1 β, and IL-6, as well as other recognized influences such as reduced lipid peroxidation and neutrophil activity. It also amplified antioxidant ability and reduced endogenous peroxidase

stain in renal ischemic tissue. So, this trial showed the efficiency of allopurinol protection against proteomic and morphological harm [132].

The IL-1β response to excess glucose concentration is arbitrated by uric acid-induced stimulation of the NLRP3 inflammasome. A study was done by Negi M, et al. showed that allopurinol considerably suppressed trophoblast emission of inflammatory IL-1β; caspase-1 activity; IL-8; RANTES; and GRO-α. Allopurinol also notably repressed more glucose-induced trophoblast secretion of anti-angiogenic sFlt-1. The existence of IL1Ra considerably repressed excess glucose-induced trophoblast IL-8 and GRO-α secretion but did not influence RANTES or sFlt-1 [133].

A study done by Guermonprez P showed that; *Plasmodium*-induced Flt3l production in mice needs Toll-Like Receptor (TLR) stimulation and type I Interferon (IFN) generation. type I IFN supports the up-regulation of xanthine dehydrogenase, which metabolizes the xanthine condensing in infected red blood cells to uric acid. Uric acid crystals stimulate mast cells to release Flt3l from a pre-synthesized membrane-related precursor. Throughout infection, Flt3l preferentially stimulates the extension of the $CD8\text{-}\alpha^{+}$ dendritic cell subset or its $BDCA3^{+}$ human being dendritic cell equal and has a much influence on the size of T cell activation, typically in the $CD8^{+}$ compartment, also noticed a positive association between plasma Flt3l amounts and malaria severity, as well as a similar relationship between plasma Flt3l levels and frequencies of circulating BDCA3+ DCs [14,134].

CONCLUSION

There is a close association between malaria and gout related genes, and we propose that the severity of malaria resulted from unwell expressing of these genes and our suggestion supported by other scientists, convincing genetic proof collected in current years shows that malaria took part to shape the human genome and it is found that variants in gene's coding for proteins expressed in red blood cells are key genetic determinants of resistance to infection and resilience to severe malaria.

DECLARATIONS

Conflict of Interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

REFERENCES

[1] Milner, Danny A. "Malaria pathogenesis." *Cold Spring Harbor Perspectives in Medicine,* Vol. 8, No. 1, 2018, p. a025569.

[2] Trampuz, Andrej, et al. "Clinical review: Severe malaria." *Critical Care,* Vol. 7, No. 4, 2003, pp. 1-9.

[3] Gowda, D., and Xianzhu Wu. "Parasite recognition and signaling mechanisms in innate immune responses to malaria." *Frontiers in Immunology,* Vol. 9, 2018, p. 3006.

[4] Clark, Ian A., et al. "Understanding the role of inflammatory cytokines in malaria and related diseases." *Travel Medicine and Infectious Disease,* Vol. 6, No. 1-2, 2008, pp. 67-81.

[5] Gallego-Delgado, Julio, et al. "A surprising role for uric acid: The inflammatory malaria response." *Current Rheumatology Reports,* Vol. 16, No. 2, 2014, p. 401.

[6] Orengo, Jamie M., et al. "Plasmodium-induced inflammation by uric acid." *PLoS Pathogens,* Vol. 4, No. 3, 2008, p. e1000013.

[7] Orengo, Jamie Marie, et al. "Uric acid is a mediator of the *Plasmodium falciparum*-induced inflammatory response." *PLoS One,* Vol. 4, No. 4, 2009, p. e5194.

[8] Gomes, Luciano Teixeira, et al. "Decreased uric acid levels in the acute phase of *Plasmodium vivax* malaria." *Journal of the Brazilian Society of Tropical Medicine,* Vol. 52, 2019.

[9] Ayede, Adejumoke Idowu, et al. "Status of some basic antioxidants in pre-and post malaria treatment in children." *Journal of Child Science,* Vol. 8, No. 01, 2018, pp. e31-e35.

[10] Zhu, Weifeng, Yan Deng, and Xiaodong Zhou. "Multiple membrane transporters and some immune regulatory genes are major genetic factors to gout." *The Open Rheumatology Journal,* Vol. 12, 2018, pp. 94-113.

[11] Bertrand, Kouam Eric, et al. "Antioxidant status of bilirubin and uric acid in patients diagnosed with *Plasmodium falciparum* malaria in Douala." *Pakistan Journal of Biological Sciences: PJBS,* Vol. 11, No. 12, 2008, pp. 1646-49.

[12] Prabhu, SS., et al. "Study of serum malondialdehyde and uric acid levels in patients with malaria." *International Journal of Clinical Biochemistry and Research*, Vol. 8, No. 3, 2021, pp. 219-21.

[13] Asahi, H., et al. "Hypoxanthine: A low molecular weight factor essential for growth of erythrocytic *Plasmodium falciparum* in a serum-free medium." *Parasitology,* Vol. 113, No. 1, 1996, pp. 19-23.

[14] Engwerda, Christian R., and Rajiv Kumar. "Mast cells fuel the fire of malaria immunopathology." *Nature Medicine,* Vol. 19, No. 6, 2013, pp. 672-74.

[15] Lopera-Mesa, Tatiana M., et al. "Plasma uric acid levels correlate with inflammation and disease severity in Malian children with *Plasmodium falciparum* malaria." *Plos One*, Vol. 7, No. 10, 2012, p. e46424.

[16] Griffith, Jason W., et al. "Pure Hemozoin is inflammatory *in vivo* and activates the NALP3 inflammasome *via* release of uric acid." *The Journal of Immunology,* Vol. 183, No. 8, 2009, pp. 5208-20.

[17] Mita-Mendoza, Neida K., et al. "A potential role for plasma uric acid in the endothelial pathology of *Plasmodium falciparum* malaria." *PLoS One,* Vol. 8, No. 1, 2013, p. e54481.

[18] Erel, Ozcan, et al. "Oxidative stress and antioxidative status of plasma and erythrocytes in patients with vivax malaria." *Clinical Biochemistry,* Vol. 30, No. 8, 1997, pp. 631-39.

[19] Ty, Maureen C., et al. "Malaria inflammation by xanthine oxidase-produced reactive oxygen species." *EMBO Molecular Medicine,* Vol. 11, No. 8, 2019, p. e9903.

[20] Jonhnston, Martin. "Gout in Maori and Pacific people linked to protection from malaria." 2014. https://www.nzherald.co.nz/nz/gout-in-maori-and-pacific-people-linked-to-protection-from-malaria/6XGO2BP7XH5H2JMRZZJQS6YKP4/

[21] Takada, Tappei, et al. "ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion." *Nucleosides, Nucleotides and Nucleic Acids,* Vol. 33, No. 4-6, 2014, pp. 275-81.

[22] Phipps-Green, Amanda J., et al. "A strong role for the *ABCG2* gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Māori, case and control sample sets." *Human Molecular Genetics,* Vol. 19, No. 24, 2010, pp. 4813-19.

[23] Wrigley, Rebekah, et al. "Pleiotropic effect of the ABCG2 gene in gout: Involvement in serum urate levels and progression from hyperuricemia to gout." *Arthritis Research & Therapy,* Vol. 22, No. 1, 2020, pp. 1-10.

[24] Caulfield, Mark J., et al. "SLC2A9 is a high-capacity urate transporter in humans." *PLoS Medicine,* Vol. 5, No. 10, 2008, p. e197.

[25] Matsuo, Hirotaka, et al. "Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia." *The American Journal of Human Genetics,* Vol. 83, No. 6, 2008, pp. 744-51.

[26] Itahana, Y., et al. "The uric acid transporter SLC2A9 is a direct target gene of the tumor suppressor p53 contributing to antioxidant defense." *Oncogene,* Vol. 34, No. 14, 2015, pp. 1799-810.

[27] Jiang, Peng, et al. "p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase." *Nature Cell Biology,* Vol. 13, No. 3, 2011, pp. 310-16.

[28] Tyberghein, Ariane, et al. "Immunopathological effects of malaria pigment or hemozoin and other crystals." *Biofactors,* Vol. 40, No. 1, 2014, pp. 59-78.

[29] Lozano, Elisa, et al. "Genetic heterogeneity of SLC22 family of transporters in drug disposition." *Journal of Personalized Medicine,* Vol. 8, No. 2, 2018, p. 14.

[30] Chiba, Toshinori, et al. "NPT1/SLC17A1 is a renal urate exporter in humans and its common gain-of-function

variant decreases the risk of renal underexcretion gout." *Arthritis & Rheumatology,* Vol. 67, No. 1, 2015, pp. 281-87.

[31] Jutabha, Promsuk, et al. "Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms." *Journal of Pharmacological Sciences,* Vol. 115, No. 2, 2011, p. 1101240504.

[32] Togawa, Natsuko, et al. "A Na^+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter." *American Journal of Physiology-Cell Physiology,* Vol. 302, No. 11, 2012, pp. C1652-60.

[33] Nakayama, Akiyoshi, et al. "A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility." *Human Cell,* Vol. 26, No. 4, 2013, pp. 133-36.

[34] Cheepala, Satish B., et al. "The ABCC4 membrane transporter modulates platelet aggregation." *Blood, The Journal of the American Society of Hematology,* Vol. 126, No. 20, 2015, pp. 2307-19.

[35] Jespersen, Thomas, Morten Grunnet, and Soren-Peter Olesen. "The KCNQ1 potassium channel: From gene to physiological function." *Physiology,* Vol. 20, No. 6, 2005, pp. 408-16.

[36] Noshiro, R., et al. "The PDZ domain protein PDZK1 interacts with human peptide transporter PEPT2 and enhances its transport activity." *Kidney International,* Vol. 70, No. 2, 2006, pp. 275-82.

[37] Manialawy, Yousef, et al. "The magnesium transporter NIPAL1 is a pancreatic islet-expressed protein that conditionally impacts insulin secretion." *Journal of Biological Chemistry,* Vol. 295, No. 29, 2020, pp. 9879-92.

[38] Friedlander, Robert M., et al. "Functional role of interleukin 1 beta (IL-1 beta) in IL-1 beta-converting enzyme-mediated apoptosis." *The Journal of Experimental Medicine,* Vol. 184, No. 2, 1996, pp. 717-24.

[39] Chuntharapai, Anan, and K. Jin Kim. "Regulation of the expression of IL-8 receptor A/B by IL-8: Possible functions of each receptor." *The Journal of Immunology,* Vol. 155, No. 5, 1995, pp. 2587-94.

[40] Li, Lina, et al. "IL-12 inhibits thymic involution by enhancing IL-7-and IL-2-induced thymocyte proliferation." *The Journal of Immunology,* Vol. 172, No. 5, 2004, pp. 2909-16.

[41] Ma, Averil, Rima Koka, and Patrick Burkett. "Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis." *Annual Review of Immunology,* Vol. 24, 2006, pp. 657-79.

[42] Verreck, Frank AW, et al. "Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria." *Proceedings of the National Academy of Sciences,* Vol. 101, No. 13, 2004, pp. 4560-65.

[43] Nishi, Tsuyoshi, et al. "Molecular and physiological functions of sphingosine 1-phosphate transporters." *Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids,* Vol. 1841, No. 5, 2014, pp. 759-65.

[44] Cain, Brian S., et al. "Tumor necrosis factor-alpha and interleukin-1 beta synergistically depress human myocardial function." *Critical Care Medicine,* Vol. 27, No. 7, 1999, pp. 1309-18.

[45] Tarzami, Sima T., et al. "MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a Gαi-independent pathway." *Biochemical and Biophysical Research Communications,* Vol. 335, No. 4, 2005, pp. 1008-16.

[46] Menu, P., and J. E. Vince. "The NLRP3 inflammasome in health and disease: The good, the bad and the ugly." *Clinical & Experimental Immunology,* Vol. 166, No. 1, 2011, pp. 1-15.

[47] Burton, Eric M., Raphaela Goldbach-Mansky, and Sumita Bhaduri-McIntosh. "A promiscuous inflammasome sparks replication of a common tumor virus." *Proceedings of the National Academy of Sciences,* Vol. 117, No. 3, 2020, pp. 1722-30.

[48] Chen, Dan, et al. "Genetic variants in peroxisome proliferator-activated receptor-γ gene are associated with risk of lung cancer in a Chinese population." *Carcinogenesis,* Vol. 29, No. 2, 2008, pp. 342-50.

[49] Merriman, Tony, and Robert Terkeltaub. "*PPARGC1B*: Insight into the expression of the gouty inflammation phenotype: *PPARGC1B* and gouty inflammation." *Rheumatology,* Vol. 56, No. 3, 2017, pp. 323-25.

[50] Divanovic, Senad, et al. "Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105." *Nature Immunology,* Vol. 6, No. 6, 2005, pp. 571-78.

[51] Tada, Yoshifumi, et al. "Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis." *Arthritis Research & Therapy,* Vol. 10, No. 5, 2008, pp. 1-11.

[52] Duan, Lihua, et al. "Decreased expression of CD14 in MSU-mediated inflammation may be associated with spontaneous remission of acute gout." *Journal of Immunology Research,* Vol. 2019, 2019.

[53] Mao, Liming, et al. "Loss-of-function CARD8 mutation causes NLRP3 inflammasome activation and Crohn's disease." *The Journal of Clinical Investigation,* Vol. 128, No. 5, 2018, pp. 1793-806.

[54] Tao, Jin-Hui, et al. "Single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis." *PLoS One,* Vol. 12, No. 8, 2017, p. e0181685.

[55] Groenestege, Wouter M. Tiel, et al. "Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia." *The Journal of Clinical Investigation,* Vol. 117, No. 8, 2007, pp. 2260-67.

[56] Zeng, Chao, et al. "Association between low serum magnesium concentration and hyperuricemia." *Magnesium Research,* Vol. 28, No. 2, 2015, pp.56-63.

[57] Chang, Chia-Hao, et al. "Gender-based impact of epidermal growth factor receptor mutation in patients with non-small cell lung cancer and previous tuberculosis." *Medicine,* Vol. 94, No. 4, 2015, p. e444.

[58] Blanc, Valerie, and Nicholas O. Davidson. "APOBEC-1-mediated RNA editing." *Wiley Interdisciplinary Reviews: Systems Biology and Medicine,* Vol. 2, No. 5, 2010, pp. 594-602.

[59] Wang, Jingyu, et al. "Expression of HNF4G and its potential functions in lung cancer." *Oncotarget,* Vol. 9, No. 26, 2018, pp. 18018-28.

[60] van Beuningen, Sam FB, et al. "TRIM46 controls neuronal polarity and axon specification by driving the formation of parallel microtubule arrays." *Neuron,* Vol. 88, No. 6, 2015, pp. 1208-26.

[61] Kur, Esther, et al. "LRP2 mediates folate uptake in the developing neural tube." *Journal of Cell Science,* Vol. 127, No. 10, 2014, pp. 2261-68.

[62] Sadik, Basma, Haydar E. Babikir, and Mohammed AR Arbab. "Clinical profile of neural tube defects in Sudanese children: Is malaria a risk factor?" *Sudanese Journal of Paediatrics,* Vol. 17, No. 1, 2017, pp. 36-41.

[63] Beck, Tobias, and Brian G. Miller. "Structural basis for regulation of human glucokinase by glucokinase regulatory protein." *Biochemistry,* Vol. 52, No. 36, 2013, pp. 6232-39.

[64] Kumar, Surendra, et al. "Significant role of ADRB3 rs4994 towards the development of coronary artery disease." *Coronary Artery Disease,* Vol. 25, No. 1, 2014, pp. 29-34.

[65] Villeger, Romain, et al. "Adh1b^{low}/Cyp26b1^{high} activity of CD90^{+} (myo) fibroblasts supports tumor-promoting inflammation in colorectal cancer." *Cancer Research*, Vol. 77, No. 13, 2017, p. 4924.

[66] Zhao, Yu, et al. "ALDH2 (Aldehyde Dehydrogenase 2) protects against hypoxia-induced pulmonary hypertension." *Arteriosclerosis, Thrombosis, and Vascular Biology,* Vol. 39, No. 11, 2019, pp. 2303-19.

[67] Groth, Alexandra, et al. "Inflammatory cytokines in pulmonary hypertension." *Respiratory Research,* Vol. 15, No. 1, 2014, pp. 1-10.

[68] Craddock, N., Michael John Owen, and Michael Conlon O'Donovan. "The Catechol-O-Methyl Transferase (COMT) gene as a candidate for psychiatric phenotypes: Evidence and lessons." *Molecular Psychiatry,* Vol. 11, No. 5, 2006, pp. 446-58.

[69] Cases, Olivier, et al. "Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA." *Science,* Vol. 268, No. 5218, 1995, pp. 1763-66.

[70] Witczak, Oliwia, et al. "Characterization of the gene encoding the human type II cGMP-dependent protein kinase (PRKG2)." *Biochemical and Biophysical Research Communications,* Vol. 245, No. 1, 1998, pp. 113-19.

[71] Montenont, Emilie, et al. "Platelet WDR1 suppresses platelet activity and is associated with cardiovascular disease." *Blood, The Journal of the American Society of Hematology,* Vol. 128, No. 16, 2016, pp. 2033-42.

[72] Kuo, Tzer-Min, et al. "URAT1 inhibition by ALPK1 is associated with uric acid homeostasis." *Rheumatology,* Vol. 56, No. 4, 2017, pp. 654-59.

[73] Liang, Yun, et al. "Distinct roles for CARMIL isoforms in cell migration." *Molecular Biology of the Cell,* Vol. 20, No. 24, 2009, pp. 5290-305.

[74] Ait-Lounis, Aouatef, et al. "The transcription factor Rfx3 regulates β-cell differentiation, function, and glucokinase expression." *Diabetes,* Vol. 59, No. 7, 2010, pp. 1674-85.

[75] Gururaj, Anupama E., et al. "Estrogen induces expression of BCAS3, a novel estrogen receptor-α coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1)." *Molecular Endocrinology,* Vol. 21, No. 8, 2007, pp. 1847-60.

[76] Drummond, Jana B., et al. "Upregulation of cornichon transcripts in the dorsolateral prefrontal cortex in schizophrenia." *Neuroreport,* Vol. 23, No. 17, 2012, pp. 1031-34.

[77] Yan, Feng, et al. "Genetic association and functional analysis of rs7903456 in FAM35A gene and hyperuricemia: A population based study." *Scientific Reports,* Vol. 8, No. 1, 2018, pp. 1-6.

[78] Kwon, Yu-Jin, et al. "Identification of genetic factors underlying the association between sodium intake habits and hypertension risk." *Nutrients,* Vol. 12, No. 9, 2020, p. 2580.

[79] Cressman, Alex M., et al. "Malaria infection alters the expression of hepatobiliary and placental drug transporters in pregnant mice." *Drug Metabolism and Disposition,* Vol. 42, No. 4, 2014, pp. 603-10.

[80] Meireles, Patrícia, et al. "GLUT1-mediated glucose uptake plays a crucial role during *Plasmodium* hepatic infection." *Cellular Microbiology,* Vol. 19, No. 2, 2017, p. e12646.

[81] Ho, Ping-Chih, and Pu-Ste Liu. "Metabolic communication in tumors: A new layer of immunoregulation for immune evasion." *Journal for Immunotherapy of Cancer,* Vol. 4, No. 1, 2016, pp. 1-9.

[82] Yunna, Chen, et al. "Macrophage M1/M2 polarization." *European Journal of Pharmacology,* Vol. 877, 2020, p. 173090.

[83] Asif, Abdul R., et al. "Presence of Organic Anion Transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells." *Pflugers Archiv-European Journal of Physiology,* Vol. 450, No. 2, 2005, pp. 88-95.

[84] Vandermosten, Leen, et al. "Adrenal hormones mediate disease tolerance in malaria." *Nature Communications,* Vol. 9, No. 1, 2018, p. 1-18.

[85] Strickland, Janae, et al. "Interleukin-6 increases the expression of key proteins associated with steroidogenesis in human NCI-H295R adrenocortical cells." *Steroids*, 119, 2017, pp. 1-17.

[86] Nussler, Andreas, et al. "TNF inhibits malaria hepatic stages *in vitro via* synthesis of IL-6." *International Immunology,* Vol. 3, No. 4, 1991, pp. 317-21.

[87] Pied, Sylviane, et al. "Inhibitory activity of IL-6 on malaria hepatic stages." *Parasite Immunology,* Vol. 13, No. 2, 1991, pp. 211-17.

[88] Pied, S., et al. "IL-6 induced by IL-1 inhibits malaria pre-erythrocytic stages but its secretion is down-regulated by the parasite." *The Journal of Immunology,* Vol. 148, No. 1, 1992, pp. 197-201.

[89] Boisson, Bertrand, et al. "The novel putative transporter NPT1 plays a critical role in early stages of *Plasmodium berghei* sexual development." *Molecular Microbiology,* Vol. 81, No. 5, 2011, pp. 1343-57.

[90] Guttery, David S., Anthony A. Holder, and Rita Tewari. "Sexual development in *Plasmodium*: Lessons from functional analyses." *PLoS Pathogens,* Vol. 8, No. 1, 2012, p. e1002404.

[91] Jutabha, Promsuk, et al. "Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate." *Journal of Biological Chemistry,* Vol. 285, No. 45, 2010, pp. 35123-32.

[92] Wan, Wei, et al. "Interleukin-37 contributes to the pathogenesis of gout by affecting PDZ domain-containing 1

protein through the nuclear factor-kappa B pathway." *Journal of International Medical Research,* Vol. 48, No. 9, 2020, p. 0300060520948717.

[93] Su, Zhangci, and Xiaoan Tao. "Current understanding of IL-37 in human health and disease." *Frontiers in Immunology,* Vol. 12, 2021, p. 2562.

[94] Onuora, Sarah. "IL-37 linked to gout pathogenesis and treatment." *Nature Reviews. Rheumatology,* Vol. 16, No. 5, 2020, p. 250.

[95] Xu, Xianxiang, et al. "Uric acid transporters hiding in the intestine." *Pharmaceutical Biology,* Vol. 54, No. 12, 2016, pp. 3151-55.

[96] Ouma, Collins, et al. "Polymorphic variability in the interleukin (IL)-1β promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1β production." *Journal of Infectious Diseases,* Vol. 198, No. 8, 2008, pp. 1219-26.

[97] Brown, Heidi, et al. "Cytokine expression in the brain in human cerebral malaria." *The Journal of Infectious Diseases,* Vol. 180, No. 5, 1999, pp. 1742-46.

[98] Moormann, Ann M., et al. "Malaria and pregnancy: Placental cytokine expression and its relationship to intrauterine growth retardation." *Journal of Infectious Diseases,* Vol. 180, No. 6, 1999, pp. 1987-93.

[99] Mahanta, Anusree, Sanjeeb Kakati, and Shashi Baruah. "The association of IL-8-251T/A polymorphism with complicated malaria in Karbi Anglong district of Assam." *Cytokine,* Vol. 65, No. 2, 2014, pp. 210-16.

[100] Lourembam, Sonia D., Clara E. Sawian, and Shashi Baruah. "Dysregulation of cytokines expression in complicated falciparum malaria with increased TGF-β and IFN-γ and decreased IL-2 and IL-12." Cytokine, Vol. 64, No. 2, 2013, pp. 503-08.

[101] Lyke, K. E., et al. "Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1β), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12 (p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls." Infection and Immunity, Vol. 72, No. 10, 2004, pp. 5630-37.

[102] Ravenhall, Matt, et al. "Novel genetic polymorphisms associated with severe malaria and under selective pressure in North-eastern Tanzania." PLoS Genetics, Vol. 14, No. 1, 2018, p. e1007172.

[103] Ishida, Hidekazu, et al. "Development of experimental cerebral malaria is independent of IL-23 and IL-17." Biochemical and Biophysical Research Communications, Vol. 402, No. 4, 2010, pp. 790-95.

[104] Belnoue, E., et al. "Control of pathogenic CD8+ T cell migration to the brain by IFN-γ during experimental cerebral malaria." Parasite Immunology, Vol. 30, No. 10, 2008, pp. 544-53.

[105] Reimer, Thornik, et al. "Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome." European Journal of Immunology, Vol. 40, No. 3, 2010, pp. 764-69.

[106] Barboza, Renato, et al. "TLR4-mediated placental pathology and pregnancy outcome in experimental malaria." Scientific Reports, Vol. 7, No. 1, 2017, pp. 1-12.

[107] Furuta, Takahisa, et al. "Mast cell-mediated immune responses through IgE antibody and Toll-like receptor 4 by malarial peroxiredoxin." European Journal of Immunology, Vol. 38, No. 5, 2008, pp. 1341-50.

[108] Wenisch, C., et al. "Elevated levels of soluble CD14 in serum of patients with acute Plasmodium falciparum malaria." Clinical & Experimental Immunology, Vol. 105, No. 1, 1996, pp. 74-78.

[109] Antonelli, Lis R., et al. "The immunology of Plasmodium vivax malaria." Immunological Reviews, Vol. 293, No. 1, 2020, pp. 163-89.

[110] Adinolfi, Elena, et al. "The P2X7 receptor: A main player in inflammation." Biochemical Pharmacology, Vol. 151, 2018, pp. 234-44.

[111] Shi, Qifang, et al. "Enhanced protection against malaria by a chimeric merozoite surface protein vaccine." Infection

and Immunity, Vol. 75, No. 3, 2007, pp. 1349-58.

[112] Yang, Annie SP, et al. "Zonal human hepatocytes are differentially permissive to Plasmodium falciparum malaria parasites." The EMBO Journal, Vol. 40, No. 6, 2021, p. e106583.

[113] Hertelendy, Frank, Miklos Toth, and Coy D. Fitch. "Malaria enhances cyclic AMP production by immature erythrocytes in vitro." Life Sciences, Vol. 25, No. 5, 1979, pp. 451-55.

[114] Izaguirre, Sadie E. "Exploring how the ALDH2* 2 mutation affects aldehyde metabolism during malaria infection." Idaho Conference on Undergraduate Research, 2019. https://scholarworks.boisestate.edu/icur/2019/Poster_Session/165/

[115] Wolfertstetter, Stefanie, Johannes P. Huettner, and Jens Schlossmann. "cGMP-dependent protein kinase inhibitors in health and disease." Pharmaceuticals, Vol. 6, No. 2, 2013, pp. 269-86.

[116] Harabor, Nicoletta. "The effect of WDR1 and a spliced isoform (WDRΔ35) on cell migration in mammalian cells." Electronic Theses and Dissertations, 2014. https://scholar.uwindsor.ca/cgi/viewcontent.cgi?referer=https://scholar.google.com/&httpsredir=1&article=6072&context=etd

[117] Bendes, Abris Adam, Petri Kursula, and Inari Kursula. "Structure and function of an atypical homodimeric actin capping protein from the malaria parasite." Research Square, 2021. https://assets.researchsquare.com/files/rs-905037/v1/266d379d-8663-4a56-9a38-399d608ae797.pdf?c=1632495247

[118] Martinez-Reyes, Camilo P., et al. "Uric acid has direct proinflammatory effects on human macrophages by increasing proinflammatory mediators and bacterial phagocytosis probably via URAT1." Biomolecules, Vol. 10, No. 4, 2020, p. 576.

[119] Shikhman, Alexander R., et al. "Cytokine regulation of facilitated glucose transport in human articular chondrocytes." The Journal of Immunology, Vol. 167, No. 12, 2001, pp. 7001-08.

[120] Mirdamadi, Kamelia, et al. "Impact of Th-17 cytokines on the regulation of transporters in human placental explants." Pharmaceutics, Vol. 13, No. 6, 2021, p. 881.

[121] Ristic, Bojana, et al. "Pharmacologic inducers of the uric acid exporter ABCG2 as potential drugs for treatment of gouty arthritis." Asian Journal of Pharmaceutical Sciences, Vol. 15, No. 2, 2020, pp. 173-80.

[122] Terkeltaub, Robert. "Update on gout: New therapeutic strategies and options." Nature Reviews Rheumatology, Vol. 6, No. 1, 2010, pp. 30-38.

[123] Huang, Lin, et al. "Association between rs2188380 and the risk of breast cancer in southwest Chinese population." Journal of Clinical Laboratory Analysis, Vol. 33, No. 5, 2019, p. e22889.

[124] Han, Lin, et al. "Epidermal growth factor gene is a newly identified candidate gene for gout." Scientific Reports, Vol. 6, No. 1, 2016, pp. 1-7.

[125] Merriman, Tony R., and Nicola Dalbeth. "The genetic basis of hyperuricaemia and gout." Joint Bone Spine, Vol. 78, No. 1, 2011, pp. 35-40.

[126] Zhou, Zhaowei, et al. "Perspectives on precision medicine in gout." Gout and Hyperuricemia, Vol. 3, No. 3, 2016, pp. 78-89

[127] Ma, Yuhe, et al. "Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer." The Journal of Immunology, Vol. 161, No. 3, 1998, pp. 1516-24.

[128] Hayashi, Reiko D., et al. "Multiple gouty tophi with bone erosion and destruction: A report of an early-onset case in an obese patient." Internal Medicine, Vol. 56, No. 9, 2017, pp. 1071-77.

[129] Dalbeth, Nicola, Thomas J. Lauterio, and Henry R. Wolfe. "Mechanism of action of colchicine in the treatment of gout." Clinical Therapeutics, Vol. 36, No. 10, 2014, pp. 1465-79.

[130] Zhang, Keke, and Changgui Li. "ABCG2 gene polymorphism rs2231142 is associated with gout comorbidities but not allopurinol response in primary gout patients of a Chinese Han male population." Hereditas, Vol. 156, No. 1, 2019, pp. 1-7.

[131] Sarma, P. S. A., Anil K. Mandal, and Harry Khamis. "Allopurinol as an additive to quinine in the treatment of acute complicated falciparum malaria." American Journal of Tropical Medicine and Hygiene, Vol. 58, No. 4, 1998, pp. 454-57.

[132] Prieto-Moure, Beatriz, et al. "Allopurinol protective effect of renal ischemia by downregulating TNF-α, IL-1β, and IL-6 response." Journal of Investigative Surgery, Vol. 30, No. 3, 2017, pp. 143-51.

[133] Negi, Masaru, et al. "Allopurinol inhibits excess glucose-induced trophoblast IL-1β and ROS production." Reproduction, Vol. 159, No. 1, 2020, pp. 73-80.

[134] Guermonprez, Pierre, et al. "Inflammatory Flt3l is essential to mobilize dendritic cells and for T-cell responses during Plasmodium infection." Nature Medicine, Vol. 19, No. 6, 2013, pp. 730-38.